-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 UiTd1Mt6Uay7BiFa1/s9cjvw1MZ788rpvq6aC4w5rPnUoMF13VN1h/ALWRIo2I+S
 R66W91/swK0FNBcSDCx8+Q==

<SEC-DOCUMENT>0001206774-11-000020.txt : 20110107
<SEC-HEADER>0001206774-11-000020.hdr.sgml : 20110107
<ACCEPTANCE-DATETIME>20110107171546
ACCESSION NUMBER:		0001206774-11-000020
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20110107
DATE AS OF CHANGE:		20110107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-171611
		FILM NUMBER:		11518261

	BUSINESS ADDRESS:	
		STREET 1:		230 CONSTITUTION DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		200 CONSTITUTION DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>geron_s3.htm
<DESCRIPTION>REGISTRATION STATEMENT FOR SPECIFIED TRANSACTIONS BY CERTAIN ISSUERS
<TEXT>
<html>
<head>
    <title>geron_s3.htm</title>
    <!-- Licensed to: DG3 I Docs, Inc. -->
    <!-- Document Created using EDGARizerAgent 5.3.0.0 -->
    <!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>

<body bgcolor="#ffffff">
<br>
<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse; ">
<tr valign="bottom">
<td colspan="2" nowrap width="100%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">As filed with the Securities and Exchange Commission on January 7, 2011</font></font></td>
</tr><tr valign="bottom">
<td align="right" nowrap width="99%" style="BORDER-BOTTOM: #000000 2pt double"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">Registration No. 333-</font></font></td>
<td align="right" nowrap width="1%" style="BORDER-BOTTOM: #000000 2pt double">&#160;&#160;&#160;&#160;&#160; </td>
</tr><tr>
<td colspan="2" nowrap width="100%" style="TEXT-ALIGN: center">
<div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-FAMILY: times new roman">UNITED STATES<br>
</font></font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-FAMILY: times new roman">SECURITIES AND EXCHANGE COMMISSION<br>
</font></font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">Washington, D.C. 20549<br>
</font></font><font size="2" style="FONT-FAMILY: times new roman">&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;<br>
</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="4" style="FONT-FAMILY: times new roman">FORM S-3<br>
</font></font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-FAMILY: times new roman">REGISTRATION STATEMENT<br>
UNDER<br>
</font></font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-FAMILY: times new roman">THE SECURITIES ACT OF 1933<br>
</font></font><font size="2" style="FONT-FAMILY: times new roman">&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;<br>
</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="5" style="FONT-FAMILY: times new roman">GERON CORPORATION</font></font><font size="5" style="FONT-FAMILY: times new roman"><br>
</font><font size="1" style="FONT-FAMILY: times new roman">(Exact Name of Registrant as Specified in Its Charter)<br>
<font size="2" style="FONT-FAMILY: times new roman">&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;</font><font size="2" style="FONT-FAMILY: times new roman"> </font></font></div>
</td>
</tr></table>
</div>

<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse; ">
<tr valign="bottom">
<td nowrap width="49%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">Delaware</font></font></td>
<td nowrap width="50%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">75-2287752</font></font></td>
</tr><tr valign="bottom">
<td nowrap width="49%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">(State or Other Jurisdiction of</font></td>
<td nowrap width="50%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">(I.R.S. Employer</font></td>
</tr><tr valign="bottom">
<td nowrap width="49%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">Incorporation or Organization)</font></td>
<td nowrap width="50%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">Identification No.)</font></td>
</tr></table>
</div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;<br>
</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">230 Constitution Drive<br>
Menlo Park, California 94025<br>
(650) 473-7700<br>
</font></font><font size="1" style="FONT-FAMILY: Times New Roman">(Address, Including Zip Code and Telephone Number,<br>
Including Area Code, of Registrant&#8217;s Principal Executive Offices)<br>
</font><font size="2" style="FONT-FAMILY: Times New Roman">&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;</font><font size="2" style="FONT-FAMILY: Times New Roman"><br>
</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">Thomas B. Okarma<br>
President and Chief Executive Officer<br>
Geron Corporation<br>
230 Constitution Drive<br>
Menlo Park, California 94025<br>
(650) 473-7700<br>
</font></font><font size="1" style="FONT-FAMILY: Times New Roman">(Name, Address, Including Zip Code and Telephone Number,<br>
Including Area Code, of Agent for Service)<br>
</font><font size="2" style="FONT-FAMILY: Times New Roman">&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;</font><font size="2" style="FONT-FAMILY: Times New Roman"><br>
Copies to:<br>
</font><font size="2" style="FONT-FAMILY: Times New Roman">&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;</font><font size="2" style="FONT-FAMILY: Times New Roman"><br>
Alan C. Mendelson, Esq.<br>
</font><font size="2" style="FONT-FAMILY: Times New Roman">Mark V. Roeder, Esq.<br>
Latham &amp; Watkins LLP<br>
</font><font size="2" style="FONT-FAMILY: Times New Roman">140 Scott Drive<br>
Menlo Park, California 94025<br>
(650) 328-4600<br>
</font><font size="2" style="FONT-FAMILY: Times New Roman">&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;</font><font size="2" style="FONT-FAMILY: Times New Roman"><br>
</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">Approximate date of commencement of proposed sale to the public: </font></font><font size="2" style="FONT-FAMILY: Times New Roman">From time to time after this Registration Statement becomes<br>
effective.<br>
&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;</font></div>

<div align="center"><font size="2">&#160;</font></div>

<div align="left">&#160;&#160;&#160;&#160; <font size="1" style="FONT-FAMILY: Times New Roman">If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. <font size="2" style="FONT-FAMILY: wingdings">o</font></font></div>

<div align="left"><font size="1" style="FONT-FAMILY: Times New Roman"><font size="3">&#160;&#160;&#160;&#160; </font>If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.&#160;<font size="2" style="FONT-FAMILY: wingdings">x</font><br>
</font><font size="1" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font size="2" style="FONT-FAMILY: wingdings">o</font><br>
</font><font size="1" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. <font size="2" style="FONT-FAMILY: wingdings">o</font><br>
</font><font size="1" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. <font size="2" style="FONT-FAMILY: wingdings">o</font><br>
</font><font size="1" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. <font size="2" style="FONT-FAMILY: wingdings">o</font><br>
</font><font size="1" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b2 of the Exchange Act.</font></div>

<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse; ">
<tr valign="bottom">
<td align="left" nowrap width="1%">&#160;&#160;&#160;&#160;&#160; </td>
<td align="left" nowrap width="1%"><font size="2" style="FONT-FAMILY: wingdings">o</font></td>
<td align="left" nowrap width="1%">&#160;&#160; </td>
<td align="left" nowrap width="47%"><font size="1" style="FONT-FAMILY: times new roman">Large accelerated filer</font></td>
<td align="left" nowrap width="1%"><font size="2" style="FONT-FAMILY: wingdings">x</font></td>
<td align="left" nowrap width="1%">&#160;&#160; </td>
<td align="left" nowrap width="48%"><font size="1" style="FONT-FAMILY: times new roman">Accelerated filer</font></td>
</tr><tr valign="bottom">
<td align="left" nowrap width="1%">&#160;</td>
<td align="left" nowrap width="1%"><font size="2" style="FONT-FAMILY: wingdings">o</font></td>
<td align="left" nowrap width="1%">&#160;</td>
<td align="left" nowrap width="47%"><font size="1" style="FONT-FAMILY: times new roman">Non-accelerated filer (Do not check if a smaller reporting company)</font></td>
<td align="left" nowrap width="1%"><font size="2" style="FONT-FAMILY: wingdings">o</font></td>
<td align="left" nowrap width="1%">&#160;</td>
<td align="left" nowrap width="48%"><font size="1" style="FONT-FAMILY: times new roman">Smaller reporting company</font></td>
</tr></table>
</div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;&#8211;</font></div>

<div align="center"><font size="2">&#160;</font></div>

<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="PADDING-RIGHT: 6pt; PADDING-LEFT: 6pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse; ">
<tr valign="bottom">
<td colspan="5" width="99%" style="BORDER-BOTTOM: #000000 2pt double; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">CALCULATION OF REGISTRATION FEE</font></font></td>
</tr><tr valign="bottom">
<td nowrap width="27%" style="BORDER-RIGHT: #000000 1pt solid; TEXT-ALIGN: center">&#160;</td>
<td nowrap width="18%" style="BORDER-RIGHT: #000000 1pt solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="1" style="FONT-FAMILY: times new roman">Amount to be</font></font></td>
<td nowrap width="18%" style="BORDER-RIGHT: #000000 1pt solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="1" style="FONT-FAMILY: times new roman">Proposed Maximum</font></font></td>
<td nowrap width="18%" style="BORDER-RIGHT: #000000 1pt solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="1" style="FONT-FAMILY: times new roman">Proposed Maximum</font></font></td>
<td nowrap width="18%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="1" style="FONT-FAMILY: times new roman">Amount of</font></font></td>
</tr><tr valign="bottom">
<td nowrap width="27%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="1" style="FONT-FAMILY: times new roman">Title of Securities to be Registered</font></font></td>
<td nowrap width="18%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="1" style="FONT-FAMILY: times new roman">Registered (1)</font></font></td>
<td nowrap width="18%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="1" style="FONT-FAMILY: times new roman">Offering Price per share</font></font></td>
<td nowrap width="18%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="1" style="FONT-FAMILY: times new roman">Aggregate Offering Price</font></font></td>
<td nowrap width="18%" style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="1" style="FONT-FAMILY: times new roman">Registration Fee</font></font></td>
</tr><tr valign="bottom">
<td align="left" nowrap width="27%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid"><font size="1" style="FONT-FAMILY: times new roman">Common Stock, par value $.001 per share (4)</font></td>
<td nowrap width="18%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font size="1" style="FONT-FAMILY: times new roman">5,261,144 shares</font></td>
<td nowrap width="18%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font size="1" style="FONT-FAMILY: times new roman">$5.29 (2)</font></td>
<td nowrap width="18%" style="BORDER-RIGHT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font size="1" style="FONT-FAMILY: times new roman">$27,831,451.76</font></td>
<td nowrap width="18%" style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font size="1" style="FONT-FAMILY: times new roman">$3,231.23 (3)</font></td>
</tr></table>
</div>

<br>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="">
<tr>
<td nowrap valign="top"><font size="1" style="FONT-FAMILY: times new roman">(1)</font></td>
<td nowrap valign="top"><font size="1" style="FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;&#160; </font></td>
<td valign="top" width="100%"><font size="1" style="FONT-FAMILY: times new roman">In the event of a stock split, stock dividend, or similar transaction involving Geron&#8217;s common stock, in order to prevent dilution, the number of shares registered shall automatically be increased to cover the additional shares in accordance with Rule 416(a) under the Securities Act of 1933.</font></td>
</tr><tr>
<td nowrap valign="top"><font size="1" style="FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="top"><font size="1" style="FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="100%"><font size="1" style="FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td nowrap valign="top"><font size="1" style="FONT-FAMILY: times new roman">(2)</font></td>
<td nowrap valign="top"><font size="1" style="FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;&#160; </font></td>
<td valign="top" width="100%"><font size="1" style="FONT-FAMILY: times new roman">The offering price is estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) and based upon the average of the high and low prices reported by the NASDAQ Global Select Market on January 5, 2011.</font></td>
</tr><tr>
<td nowrap valign="top"><font size="1" style="FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="top"><font size="1" style="FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="100%"><font size="1" style="FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td nowrap valign="top"><font size="1" style="FONT-FAMILY: times new roman">(3)</font></td>
<td nowrap valign="top"><font size="1" style="FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;&#160; </font></td>
<td valign="top" width="100%"><font size="1" style="FONT-FAMILY: times new roman">Calculated in accordance with Rule 457(o) under the Securities Act of 1933.</font></td>
</tr><tr>
<td nowrap valign="top"><font size="1" style="FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="top"><font size="1" style="FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="100%"><font size="1" style="FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td nowrap valign="top"><font size="1" style="FONT-FAMILY: times new roman">(4)</font></td>
<td nowrap valign="top"><font size="1" style="FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="top" width="100%"><font size="1" style="FONT-FAMILY: times new roman">Each share of Common Stock being registered hereunder, if issued prior to the termination by the Company of its Rights Agreement dated as of July 20, 2001, will include one preferred share purchase right. Prior to the occurence of certain events, the preferred share purchase rights will not be exercisable or evidenced separately from the Common Stock.</font></td>
</tr></table>
</div>

<div align="left">&#160;</div>

<div style="TEXT-ALIGN: left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL HEREAFTER BECOME EFFECTIVE IN </font></font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">ACCORDANCE WITH SECTION 8(A) OF THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE SECURITIES AND EXCHANGE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(A), MAY DETERMINE. </font></font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div>
<div style="TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">THE INFORMATION IN THIS PROSPECTUS IS NOT COMPLETE AND MAY BE CHANGED. THE SELLING STOCKHOLDER MAY NOT SELL THESE SECURITIES UNTIL THE REGISTRATION STATEMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION IS EFFECTIVE. THIS PROSPECTUS IS NOT AN OFFER TO SELL THESE SECURITIES AND IT IS NOT SOLICITING AN OFFER TO BUY THESE SECURITIES IN ANY STATE WHERE THE OFFER OR SALE IS NOT PERMITTED.</font></font></div>
</div>

<div>&#160;</div>

<div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">SUBJECT TO COMPLETION, DATED JANUARY 7, 2011 </font></font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">PROSPECTUS </font></font></div>

<div>&#160;</div>

<div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">5,261,144 SHARES OF </font></font></div>

<div>&#160;</div>

<div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">GERON CORPORATION </font></font></div>

<div>&#160;</div>

<div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">COMMON STOCK </font></font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">Our common stock is traded on the NASDAQ Global Select Market under the symbol &#8220;GERN.&#8221; On January 5, 2011, the closing price of our common stock was $5.34.</font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">This prospectus relates to the sale of up to 5,261,144 shares of our common stock by the selling stockholder, Angiochem, Inc. We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholder.</font></div>

<div>&#160;</div>

<div><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3">&#160;&#160;&#160;&#160; </font>The selling stockholder or its pledgees,&#160;donees, transferees or successors-in-interest may offer and sell or otherwise dispose of the shares of common stock described in this prospectus from time to time through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. The selling stockholder will bear all commissions and discounts, if any, attributable to the sales of shares. We will bear all other costs, expenses and fees in connection with the registration of the shares. See &#8220;Plan of Distribution&#8221; beginning on page 22 for more information about how the selling stockholder may sell or dispose of its shares of common stock.</font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">INVESTING IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. SEE &#8220;RISK FACTORS&#8221; BEGINNING ON PAGE 2. </font></font></div>

<div>&#160;</div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">______________________</font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: left">&#160;&#160;&#160;&#160;&#160;<font size="2" style="FONT-FAMILY: Times New Roman">Neither the Securities and Exchange Commission (the SEC) nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</font></div>

<div>&#160;</div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">______________________ </font></div>

<div>&#160;</div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">The date of this prospectus is&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2011. </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">TABLE OF CONTENTS </font></font></div>

<div>&#160;</div>

<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse; ">
<tr valign="bottom">
<td align="left" nowrap width="98%">&#160;</td>
<td align="right" nowrap width="1%">&#160;&#160;&#160;&#160;&#160; </td>
<td align="right" nowrap width="1%" style="BORDER-BOTTOM: #000000 1pt solid"><font size="2" style="FONT-FAMILY: times new roman">Page</font></td>
</tr><tr valign="bottom">
<td align="left" nowrap width="98%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">ABOUT THIS PROSPECTUS</font></td>
<td align="right" nowrap width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="right" nowrap width="1%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">1</font></td>
</tr><tr valign="bottom">
<td align="left" nowrap width="98%"><font size="2" style="FONT-FAMILY: times new roman">ABOUT GERON</font></td>
<td align="right" nowrap width="1%">&#160;</td>
<td align="right" nowrap width="1%"><font size="2" style="FONT-FAMILY: times new roman">2</font></td>
</tr><tr valign="bottom">
<td align="left" nowrap width="98%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">RISK FACTORS</font></td>
<td align="right" nowrap width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="right" nowrap width="1%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">2</font></td>
</tr><tr valign="bottom">
<td align="left" nowrap width="98%"><font size="2" style="FONT-FAMILY: times new roman">FORWARD-LOOKING STATEMENTS</font></td>
<td align="right" nowrap width="1%">&#160;</td>
<td align="right" nowrap width="1%"><font size="2" style="FONT-FAMILY: times new roman">19</font></td>
</tr><tr valign="bottom">
<td align="left" nowrap width="98%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">USE OF PROCEEDS</font></td>
<td align="right" nowrap width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="right" nowrap width="1%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">20</font></td>
</tr><tr valign="bottom">
<td align="left" nowrap width="98%"><font size="2" style="FONT-FAMILY: times new roman">SELLING STOCKHOLDER</font></td>
<td align="right" nowrap width="1%">&#160;</td>
<td align="right" nowrap width="1%"><font size="2" style="FONT-FAMILY: times new roman">21</font></td>
</tr><tr valign="bottom">
<td align="left" nowrap width="98%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">PLAN OF DISTRIBUTION</font></td>
<td align="right" nowrap width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="right" nowrap width="1%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">22</font></td>
</tr><tr valign="bottom">
<td align="left" nowrap width="98%"><font size="2" style="FONT-FAMILY: times new roman">VALIDITY OF THE SECURITIES</font></td>
<td align="right" nowrap width="1%">&#160;</td>
<td align="right" nowrap width="1%"><font size="2" style="FONT-FAMILY: times new roman">23</font></td>
</tr><tr valign="bottom">
<td align="left" nowrap width="98%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">EXPERTS</font></td>
<td align="right" nowrap width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="right" nowrap width="1%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">23</font></td>
</tr><tr valign="bottom">
<td align="left" nowrap width="98%"><font size="2" style="FONT-FAMILY: times new roman">MATERIAL CHANGES</font></td>
<td align="right" nowrap width="1%">&#160;</td>
<td align="right" nowrap width="1%"><font size="2" style="FONT-FAMILY: times new roman">23</font></td>
</tr><tr valign="bottom">
<td align="left" nowrap width="98%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">WHERE YOU CAN FIND MORE INFORMATION</font></td>
<td align="right" nowrap width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="right" nowrap width="1%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">23</font></td>
</tr><tr valign="bottom">
<td align="left" nowrap width="98%"><font size="2" style="FONT-FAMILY: times new roman">DOCUMENTS WE HAVE INCORPORATED BY REFERENCE</font></td>
<td align="right" nowrap width="1%">&#160;</td>
<td align="right" nowrap width="1%"><font size="2" style="FONT-FAMILY: times new roman">24</font></td>
</tr></table>
</div>

<br>
<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">ABOUT THIS PROSPECTUS</font></font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">You should rely only on the information contained or incorporated by reference in this prospectus. We have not, and the selling stockholder has not, authorized anyone to provide you with information different from that contained in this prospectus. The selling stockholder is offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where it is lawful to do so. The information in this prospectus is accurate only as of the date of this prospectus and any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or any sale of our common stock.</font></div>

<div align="left"><font size="2">&#160;</font></div>

<div style="TEXT-ALIGN: center"><font size="2">1</font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">ABOUT GERON </font></font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases. We are advancing anti-cancer therapies through multiple Phase 2 clinical trials in different cancers by targeting the enzyme telomerase and with a compound designed to penetrate the blood-brain barrier (BBB). We are developing cell therapy products from differentiated human embryonic stem cells for multiple indications, including central nervous system (CNS) disorders, heart failure, diabetes and osteoarthritis, and have initiated a Phase 1 clinical trial in spinal cord injury.</font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">We were incorporated in 1990 under the laws of Delaware. Our principal executive offices are located at 230 Constitution Drive, Menlo Park, California 94025 and our telephone number is (650) 473-7700.</font></div>

<div>&#160;</div>

<div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">RISK FACTORS </font></font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">Our business is subject to various risks, including those described below. You should carefully consider these risk factors, together with all of the other information included in this prospectus and the risk factors set forth under the heading &#8220;Risk Factors&#8221; in our future filings under the Securities Exchange Act of 1934, as amended, which are incorporated by reference into this prospectus. For more information, see the section entitled &#8220;Documents We Have Incorporated by Reference.&#8221; Any of these risks could materially adversely affect our business, operating results and financial condition.</font></div>

<div>&#160;</div>

<div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">RISKS RELATED TO OUR BUSINESS </font></font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Our business is at an early stage of development. </font></font></font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">Our business is at an early stage of development, in that we do not yet have product candidates in late-stage clinical trials or on the market. We have sponsored six Phase 1 or 1 / 2 trials of our lead anti-cancer drug candidate, imetelstat, in patients with chronic lymphoproliferative diseases, solid tumor malignancies, non-small cell lung cancer, breast cancer and multiple myeloma and all of those trials have now completed patient enrollment. We are advancing imetelstat through Phase 2 trials in four different malignancies and each of these trials is currently open for patient enrollment. Patient enrollment for the trial of our telomerase cancer vaccine, GRNVAC1, in patients with acute myelogenous leukemia is now complete. In October 2010, the first patient was enrolled into the Phase 1 multi-center trial that is designed to establish the safety of GRNOPC1 in patients with &#8220;complete&#8221; American Spinal I
njury Association (ASIA) grade A subacute thoracic spinal cord injuries.</font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">On December 6, 2010, we entered into an exclusive license agreement with Angiochem, Inc. (Angiochem) with respect to Angiochem&#8217;s proprietary peptide technology that facilitates the transfer of anti-cancer compounds across the blood-brain barrier (BBB) to enable the treatment of primary brain cancers and cancers that have metastasized to the brain. The exclusive license agreement covers Angiochem&#8217;s proprietary receptor-targeting peptides conjugated to tubulin disassembly inhibitors, including ANG1005 (now GRN1005), a novel taxane derivative.</font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">Our ability to develop product candidates that progress to and through clinical trials is subject to our ability to, among other things:</font></div>

<ul style="FONT-SIZE: 10pt">
<li><font size="2" style="FONT-FAMILY: Times New Roman">succeed in our research and development efforts;<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">select therapeutic compounds or cell therapies for development;<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">obtain required regulatory approvals;<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">finance, or obtain additional financing for, our clinical trials;<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">manufacture product candidates; and<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">collaborate successfully with clinical trial sites, academic institutions, physician investigators, clinical research organizations and other third parties.</font> </li>
</ul>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">2 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">Potential lead drug compounds or other product candidates and technologies require significant preclinical and clinical testing prior to regulatory approval in the United States and other countries. Our product candidates may prove to have undesirable and unintended side effects or other characteristics adversely affecting their safety, efficacy or cost-effectiveness that could prevent or limit their commercial use. In addition, our product candidates may not prove to be more effective for treating disease or injury than current therapies. Accordingly, we may have to delay or abandon efforts to research, develop or obtain regulatory approvals to market our product candidates. In addition, we will need to determine whether any of our potential products can be manufactured in commercial quantities at an acceptable cost. Our research and development efforts may not result in a product that can be or will be approved b
y regulators or marketed successfully. Competitors may have proprietary rights which prevent us from developing and marketing our products or they may sell similar, superior or lower-cost products. Because of the significant scientific, regulatory and commercial milestones that must be reached for any of our development programs or product candidates to be successful, any program or product candidate may be abandoned, even after we have expended significant resources, such as our investments or prospective investments in telomerase technology, receptor-targeting peptide technology to cross the BBB, hESCs, imetelstat, GRN1005 (formerly ANG1005), GRNVAC1 and GRNOPC1, which could adversely affect our business and materially and adversely affect our stock price.</font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">The science and technology of telomere biology, telomerase, receptor-targeting peptides that cross the BBB and hESCs are relatively new. Further, the information we have related to the ability of GRN1005 (formerly ANG1005) to penetrate brain tissue and its anti-tumor activity is preliminary and based on Phase 1 clinical studies. There is no precedent for the successful commercialization of therapeutic product candidates based on these technologies. Therefore, our development programs are particularly risky and uncertain. In addition, we, our licensees or our collaborators must undertake significant research and development activities to develop product candidates based on these technologies, which will require additional funding and may take years to accomplish, if ever.</font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Restrictions on the use of hESCs, political commentary and the ethical and social implications of research involving hESCs could prevent us from developing or gaining acceptance for commercially viable products based upon such stem cells and adversely affect the market price of our common stock.</font></font></font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">Some of our most important programs involve the use of stem cells that are derived from human embryos. The use of hESCs gives rise to ethical and social issues regarding the appropriate use of these cells. Our research related to hESCs may become the subject of adverse commentary or publicity, which could significantly harm the market price of our common stock.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Some political and religious groups have voiced opposition to our technology and practices. We use stem cells derived from human embryos that had been created for </font><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">in vitro</font></font><font size="2" style="FONT-FAMILY: Times New Roman"> fertilization procedures but were no longer desired or suitable for that use and were donated with appropriate informed consent. Many research institutions, including some of our scientific collaborators, have adopted policies regarding the ethical use of human embryonic tissue. These policies may have the effect of limiting the scope of research conducted using hESCs, thereby impairing our ability to conduct research in this field.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Government-imposed restrictions with respect to use of embryos or hESCs in research and development could have a material effect on our business, including:</font></div>

<ul style="FONT-SIZE: 10pt">
<li><font size="2" style="FONT-FAMILY: Times New Roman">harming our ability to establish critical partnerships and collaborations;<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">delaying or preventing progress in our research, product development or clinical testing; and<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">preventing commercialization of therapies derived from hESCs.</font> </li>
</ul>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">These potential effects and others may result in a decrease in the market price of our common stock.</font></div>

<div align="left"><font size="2">&#160;</font></div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">3 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Changes in governmental regulations relating to funding of stem cell research may also materially impact our product development programs and result in an increase to the volatility of the market price of </font><font size="2" style="FONT-FAMILY: Times New Roman"><font style="FONT-FAMILY: Times New Roman">our common stock. For example, in March 2009 President Obama issued Executive Order 13505, entitled &#8220;Removing Barriers to Responsible Scientific Research Involving Human Stem Cells.&#8221; As a result, the Secretary of Health and Human Services, through the Director of the National Institutes of Health (NIH), issued new guidelines relating to human stem cell research to allow federal funding for research using hESCs derived from embryos created by </font><font style="DISPLAY: inline; FONT-STYLE: italic"><font style="FONT-FAMILY: Times New Roman">in v
itro</font></font><font style="FONT-FAMILY: Times New Roman"> fertilization for reproductive purposes, but are no longer needed for that purpose. However, in August 2010 the Federal District Court for the District of Columbia issued a preliminary injunction prohibiting federal funding for hESC research. In September 2010, a federal appeals court lifted the injunction. A final ruling is expected in 2011. Meanwhile, certain states are considering enacting, or already have enacted, legislation relating to stem cell research, including California, whose voters approved Proposition 71 to provide state funds for stem cell research in November 2004. In the United Kingdom and other countries, the use of embryonic or fetal tissue in research (including the derivation of hESCs) is regulated by the government, whether or not the research involves government funding.</font></font></div>

<div>&#160;</div>

<div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">RISKS RELATED TO OUR FINANCIAL POSITION AND NEED FOR ADDITIONAL<br>
FINANCING </font></font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">We have a history of losses and anticipate future losses, and continued losses could impair our ability to sustain operations.</font></font></font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">We have incurred operating losses every year since our operations began in 1990. As of September 30, 2010, our accumulated deficit was approximately $629.3 million. Losses have resulted principally from costs incurred in connection with our research and development activities and from general and administrative costs associated with our operations. We expect to incur additional operating losses and, as our development efforts and clinical testing activities continue, our operating losses may increase in size.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Substantially all of our revenues to date have been research support payments under collaboration agreements and revenues from our licensing arrangements. We may be unsuccessful in entering into any new corporate collaboration or license agreements that result in revenues. We do not expect that the revenues generated from these arrangements will be sufficient alone to continue or expand our research or development activities and otherwise sustain our operations.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>While we receive royalty revenue from licenses, we do not currently expect to receive sufficient royalty revenues from these licenses to independently sustain our operations. Our ability to continue or expand our research and development activities and otherwise sustain our operations is dependent on our ability, alone or with others, to, among other things, manufacture and market therapeutic products.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>We also expect to experience negative cash flow for the foreseeable future as we fund our operating losses and capital expenditures. This will result in decreases in our working capital, total assets and stockholders&#8217; equity, which may not be offset by future financings. We will need to generate significant revenues to achieve profitability. We may not be able to generate these revenues, and we may never achieve profitability. Our failure to achieve profitability could negatively impact the market price of our common stock. Even if we do become profitable, we cannot assure you that we would be able to sustain or increase profitability on a quarterly or annual basis.</font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">We will need additional capital to conduct our operations and develop our product candidates, and our ability to obtain the necessary funding is uncertain.</font></font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>We will require substantial capital resources in order to conduct our operations and develop our product candidates, and we cannot assure you that our existing capital resources, interest income and equipment financing arrangement will be sufficient to fund future planned operations. The timing and degree of any future capital requirements will depend on many factors, including:</font></div>

<div>&#160;</div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">4 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<ul style="FONT-SIZE: 10pt">
<li><font size="2" style="FONT-FAMILY: Times New Roman">the accuracy of the assumptions underlying our estimates for our capital needs for the 2011 fiscal year and beyond;<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">the magnitude and scope of our research and development programs;<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">the progress we make in our research and development programs, preclinical development and clinical trials;<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">our ability to establish, enforce and maintain strategic arrangements for research, development, clinical testing, manufacturing and marketing;<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">the number and type of product candidates that we pursue;<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">the time and costs involved in obtaining regulatory approvals and clearances; and<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims.</font> </li>
</ul>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">We do not have any committed sources of capital, other than our equipment financing facility. Additional financing through strategic collaborations, public or private equity financings, capital lease transactions or other financing sources may not be available on acceptable terms, or at all. The receptivity of the public and private equity markets to proposed financings is substantially affected by the general economic, market and political climate and by other factors which are unpredictable and over which we have no control. Additional equity financings, if we obtain them, could result in significant dilution to our stockholders. Further, in the event that additional funds are obtained through arrangements with collaborative partners, these arrangements may require us to relinquish rights to some of our technologies, product candidates or proposed products that we would otherwise seek to develop and commercialize
 ourselves. If sufficient capital is not available, we may be required to delay, reduce the scope of or eliminate one or more of our programs, any of which could have a material adverse effect on our business.</font></div>

<div>&#160;</div>

<div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">RISKS RELATED TO CLINICAL AND COMMERCIALIZATION ACTIVITIES </font></font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Delays in the commencement of clinical testing of our current and potential product candidates could result in increased costs to us and delay our ability to generate revenues.</font></font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>The commencement of clinical trials can be delayed for a variety of reasons, including delays in:</font></div>

<ul style="FONT-SIZE: 10pt">
<li><font size="2" style="FONT-FAMILY: Times New Roman">demonstrating sufficient safety and efficacy to obtain regulatory clearance to commence a clinical trial;<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">manufacturing sufficient quantities or producing drugs meeting our quality standards of a product candidate;<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">obtaining approval of an IND application or proposed trial design from the FDA;<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">reaching agreement on acceptable terms with our collaborators on all aspects of the clinical trial, including the contract research organizations (CROs) and the trial sites; and<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">obtaining institutional review board approval to conduct a clinical trial at a prospective site.</font> </li>
</ul>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>In addition, clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size and nature of the patient population, the nature of the protocol, the proximity of patients to clinical sites, the availability of effective treatments for the relevant disease, and the eligibility criteria for the clinical trial. Delays in commencing clinical testing of our product candidates could prevent or delay us from obtaining approval for our product candidates.</font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">We do not have experience as a company in conducting large-scale clinical trials, or in other areas required for the successful commercialization and marketing of our product candidates.</font></font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>We have no experience as a company in conducting large-scale, late stage clinical trials. We cannot be certain that planned clinical trials will begin or be completed on time, if at all. Large-scale trials would require either additional financial and management resources, or reliance on third-party clinical <font size="2" style="FONT-FAMILY: Times New Roman">investigators, CROs or consultants. Relying on third-party clinical investigators or CROs may force us to encounter delays that are outside of our control. Any such delays could have a material adverse effect on our business.</font></font></div>

<div><font size="2" style="FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">5 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">We also do not currently have marketing and distribution capabilities for our product candidates. Developing an internal sales and distribution capability would be an expensive and time-consuming process. We may enter into agreements with third parties that would be responsible for marketing and distribution. However, these third parties may not be capable of successfully selling any of our product candidates. The inability to commercialize and market our product candidates could materially adversely affect our business.</font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Obtaining regulatory approvals to market our product candidates in the United States and other countries is a costly and lengthy process and we cannot predict whether or when we will be permitted to commercialize our product candidates.</font></font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Federal, state and local governments in the United States and governments in other countries have significant regulations in place that govern many of our activities and may prevent us from creating commercially viable products from our discoveries. The regulatory process, particularly for biopharmaceutical product candidates like ours, is uncertain, can take many years and requires the expenditure of substantial resources.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Our potential product candidates will require extensive preclinical and clinical testing prior to submission of any regulatory application to commence commercial sales. In particular, human pharmaceutical therapeutic product candidates are subject to rigorous requirements of the FDA in the United States and similar health authorities in other countries in order to demonstrate safety and efficacy. Data obtained from preclinical and clinical activities is susceptible to varying interpretations that could delay, limit or prevent regulatory agency approvals. In addition, delays or rejections may be encountered as a result of changes in regulatory agency policy during the period of product development and/or the period of review of any application for regulatory agency approval for a product candidate.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Any product candidate that we or our collaborators develop must receive all relevant regulatory agency approvals before it may be marketed in the United States or other countries. Obtaining regulatory approval is a lengthy, expensive and uncertain process. Because certain of our product candidates involve the application of new technologies or are based upon a new therapeutic approach, they may be subject to substantial additional review by various government regulatory authorities, and, as a result, the process of obtaining regulatory approvals for them may proceed more slowly than for product candidates based upon more conventional technologies.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Delays in obtaining regulatory agency approvals could:</font></div>

<ul style="FONT-SIZE: 10pt">
<li><font size="2" style="FONT-FAMILY: Times New Roman">significantly harm the marketing of any products that we or our collaborators develop;<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">impose costly procedures upon our activities or the activities of our collaborators;<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">diminish any competitive advantages that we or our collaborators may attain; or<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">adversely affect our ability to receive royalties and generate revenues and profits.</font> </li>
</ul>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">Even if we commit the necessary time and resources, the required regulatory agency approvals may not be obtained for any product candidates developed by us or in collaboration with us. If we obtain regulatory agency approval for a new product, this approval may entail limitations on the indicated uses for which it can be marketed that could limit the potential commercial use of the product.</font></div>

<div>&#160;</div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">6 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Failure to achieve continued compliance with government regulation over approved products could delay or halt commercialization of our products.</font></font></font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">Approved products and their manufacturers are subject to continual review, and discovery of previously unknown problems with a product or its manufacturer may result in restrictions on the product or manufacturer, including withdrawal of the product from the market. The future sale by us or our collaborators of any commercially viable product will be subject to government regulation from several standpoints, including the processes of:</font></div>

<ul style="FONT-SIZE: 10pt">
<li><font size="2" style="FONT-FAMILY: Times New Roman">manufacturing;<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">advertising and promoting;<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">selling and marketing;<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">labeling; and<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">distribution.</font> </li>
</ul>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">If, and to the extent that, we are unable to comply with these regulations, our ability to earn revenues will be materially and negatively impacted.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Failure to comply with regulatory requirements can result in severe civil and criminal penalties, including but not limited to:</font></div>

<ul style="FONT-SIZE: 10pt">
<li><font size="2" style="FONT-FAMILY: Times New Roman">recall or seizure of products;<br>
&#160;</font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">injunction against the manufacture, distribution and sales and marketing of products; and<br>
&#160; </font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">criminal prosecution.</font> </li>
</ul>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">The imposition of any of these penalties or other commercial limitations could significantly impair our business, financial condition and results of operations.</font></div>

<div>&#160;</div>

<div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">RISKS RELATED TO PROTECTING OUR INTELLECTUAL PROPERTY</font></font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Impairment of our intellectual property rights may adversely affect the value of our technologies and product candidates and limit our ability to pursue their development.</font></font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Protection of our proprietary technology is critically important to our business. Our success will depend in part on our ability to obtain and enforce our patents and maintain trade secrets, both in the United States and in other countries. Further, our patents may be challenged, invalidated or circumvented, and our patent rights may not provide proprietary protection or competitive advantages to us. In the event that we are unsuccessful in obtaining and enforcing patents, we may not be able to further develop or commercialize our product candidates and our business would be negatively impacted.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>The patent positions of pharmaceutical and biopharmaceutical companies, including ours, are highly uncertain and involve complex legal and technical questions. In particular, legal principles for biotechnology and pharmaceutical patents in the United States and in other countries are evolving, and the extent to which we will be able to obtain patent coverage to protect our technology, or enforce issued patents, is uncertain. In the United States, recent court decisions in patent cases as well as proposed legislative changes to the patent system only exacerbate this uncertainty. Furthermore, significant amendments to the regulations governing the process of obtaining patents were proposed in a new rule package by the United States Patent and Trademark Office (the Patent Office) in 2007. The proposed new rules were widely regarded as detrimental to the intere
sts of biotechnology and pharmaceutical companies. The implementation of the rule package was blocked by a court injunction requested by a pharmaceutical company. The Patent Office challenged the court decision through an appeal to the U.S. Court of Appeals for the Federal Circuit (CAFC), but the appeal was dismissed in November 2009, after the Patent Office <font size="2" style="FONT-FAMILY: Times New Roman">changed course and rescinded the proposed new rules. At this point we do not know whether the Patent Office will attempt to introduce new rules to replace those that were recently withdrawn or whether any such new rules would also be challenged.</font></font></div>

<div><font size="2" style="FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">7 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">In Europe, the European Patent Convention prohibits the granting of European patents for inventions that concern &#8220;uses of human embryos for industrial or commercial purposes.&#8221; The European Patent Office (EPO) was earlier interpreting this prohibition broadly, and applying it to reject claims in any patent application that pertained to hESCs. An early patent application filed by the Wisconsin Alumni Research Foundation (WARF) with claims covering the original isolation of hESCs was appealed as a test case, and examination of other hESC patent applications was suspended while that case was heard. In November 2008, the EPO Enlarged Board of Appeals held that the claims in the WARF application were unpatentable. Geron holds a worldwide license under this patent family, and since the decision is not subject to further appeal, this WARF patent family will not afford protection to Geron&#8217;s hESC-based prod
uct candidates in Europe. However, the reason given by the EPO for the decision was narrowly focused: the EPO found the claims objectionable on the basis that at the time that WARF filed the patent application it was necessary to use a human embryo to obtain hESCs since no cell lines were available. In contrast, the hESCs that we use, and which we employed in the technologies claimed in our own European patent applications, were sourced from established hESC lines. Consequently, the decision in the WARF case does not directly address the patentability of the subject matter in our filings. The EPO has recently restarted examination of hESC patent applications, but its application of the WARF decision to these later filed cases is still developing. At this time, we do not know whether or to what extent we will be able to obtain patent protection for our hESC technologies in Europe. If we are unable to protect our inventions related to hESCs in Europe, our business would be negatively impacted.</font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Challenges to our patent rights can result in costly and time-consuming legal proceedings that may prevent or limit development of our product candidates.</font></font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Publication of discoveries in scientific or patent literature tends to lag behind actual discoveries by at least several months and sometimes several years. Therefore, the persons or entities that we or our licensors name as inventors in our patents and patent applications may not have been the first to invent the inventions disclosed in the patent applications or patents, or the first to file patent applications for these inventions. As a result, we may not be able to obtain patents for discoveries that we otherwise would consider patentable and that we consider to be extremely significant to our future success.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Where more than one party seeks U.S. patent protection for the same technology, the Patent Office may declare an interference proceeding in order to ascertain the party to which the patent should be issued. Patent interferences are typically complex, highly contested legal proceedings, subject to appeal. They are usually expensive and prolonged, and can cause significant delay in the issuance of patents. Moreover, parties that receive an adverse decision in an interference can lose important patent rights. Our pending patent applications, or our issued patents, may be drawn into interference proceedings which may delay or prevent the issuance of patents, or result in the loss of issued patent rights. By way of example, we are currently a party to an interference proceeding that involves patent filings for making endoderm cells from hESCs. We requested that 
the Patent Office declare this interference after Novocell Inc. (recently renamed ViaCyte, Inc. (ViaCyte)) was granted patent claims that conflict with subject matter we filed in an earlier patent application. A number of outcomes are possible: (i) the claims may be awarded to ViaCyte; (ii) the claims may be awarded to Geron, or (iii) neither party might be found to be entitled to the claims. The decision from the Patent Office may also be subject to appeal. Since the interference is still ongoing, we cannot predict what the outcome will be.</font></div>

<div>&#160;</div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">8 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Outside of the United States, certain jurisdictions, such as Europe, New Zealand and Australia, permit oppositions to be filed against the granting of patents. Because our intent is to commercialize products internationally, securing both proprietary protection and freedom to operate outside of the United States is important to our business. We are involved in both opposing the grant of patents to others through such opposition proceedings and in defending our patent applications against oppositions filed by others. For example, we have been involved in two patent oppositions before the EPO with a Danish company, Pharmexa. Pharmexa (which acquired the Norwegian company GemVax in 2005) is developing a cancer </font>vaccine that employs a short telomerase peptide to induce an immune response against telomera
se and is conducting a Phase 3 clinical trial. Pharmexa obtained a European patent with broad claims to the use of telomerase vaccines for the treatment of cancer, and Geron opposed that patent in 2004. In 2005, the Opposition Division (OD) of the EPO revoked the claims originally granted to Pharmexa, but permitted Pharmexa to add new, narrower claims limited to five specific small peptide fragments of telomerase. The decision was appealed to the Technical Board of Appeals (TBA). In August 2007, the TBA ruled, consistent with the decision of the OD, that Pharmexa was not entitled to the originally granted broad claims but was only entitled to the narrow claims limited to the five small peptides. In late 2008, Pharmexa reported that it sold its telomerase vaccine program to a Korean company, KAEL Co. Ltd., and the continuing company now operates under the name KAEL-GemVax. KAEL-GemVax was recently granted a further related European patent covering its telomerase peptide vaccine against which we have filed an 
opposition. That opposition is ongoing and we cannot predict the outcome. </font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">In parallel, Pharmexa opposed a European patent held by Geron, the claims of which cover many facets of human telomerase, including the use of telomerase peptides in cancer vaccines. In June 2006, the OD of the EPO revoked three of the granted claims in Geron&#8217;s patent, specifically the three claims covering telomerase peptide cancer vaccines. We have appealed that decision to the TBA, and that appeal is still pending. Because this appeal is ongoing, the outcome cannot be determined at this time. We have recently been awarded a second European patent with claims to telomerase peptides, and this patent has also been opposed by KAEL-GemVax. We cannot predict the outcome of this opposition or any subsequent appeal of the decision in the opposition. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>European opposition and appeal proceedings can take several years to reach final decision. The oppositions discussed above reflect the complexity of the patent landscape in which we operate, and illustrate the risks and uncertainties. We are also currently involved in other patent opposition proceedings in Europe and Australia. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Patent opposition proceedings are not currently available in the U.S. patent system. Legislation was previously proposed to introduce them, but so far has not been enacted into law. However, issued U.S. patents can be reexamined by the Patent Office at the request of a third party. Patents owned or licensed by Geron may therefore be subject to reexamination. As in any legal proceeding, the outcome of patent reexaminations is uncertain, and a decision adverse to our interests could result in the loss of valuable patent rights. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>In July 2006, requests were filed on behalf of the Foundation for Taxpayer and Consumer Rights (now renamed as &#8220;Consumer Watchdog&#8221;) for reexamination of three issued U.S. patents owned by WARF and relating to hESCs. These three patents (U.S. Patent Nos. 5,843,780, 6,200,806 and 7,029,913), which are the U.S. equivalents of the European WARF case discussed above, are licensed to Geron pursuant to a January 2002 license agreement with WARF. The license agreement conveys exclusive rights to Geron under the WARF patents for the development and commercialization of therapeutics based on neural cells, cardiomyocytes and pancreatic islet cells, derived from hESCs, as well as non-exclusive rights for other product opportunities. In October 2006, the Patent Office initiated the reexamination proceedings. After initially rejecting the patent claims, the P
atent Office issued decisions in all three cases upholding the patentability of the claims as amended. The decisions to uphold the 5,843,780 and 6,200,806 patents are final and not subject to further appeal. Consumer Watchdog appealed the decision on the 7,029,913 patent. In April 2010, the Board of Patent Appeals and Interferences reversed the earlier decision of the Patent Office on the 7,029,913 patent. WARF will now have the opportunity to present amended claims for further examination at the Patent Office. We cooperated with WARF in these reexamination actions and expect that WARF will continue to vigorously defend its patent position. The final outcome of these or of any future reexamination proceedings cannot be determined at this time. Reduction or loss of claim scope in these WARF embryonic stem cell patents could negatively impact Geron&#8217;s proprietary position in this technology. </font></div>

<div>&#160;</div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">9 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<!-- part b-->
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3">&#160;&#160;&#160;&#160; </font>As more groups become engaged in scientific research and product development in the areas of telomerase biology, receptor-targeting peptides that cross the BBB and embryonic stem cells, the risk of our patents being challenged through patent interferences, oppositions, reexaminations, litigation or other means will likely increase. Challenges to our patents through these procedures can be extremely expensive and time-consuming, even if the outcome is favorable to us. An adverse outcome in a patent dispute could severely harm our business by:</font></div>

<ul style="FONT-SIZE: 10pt">
<li>causing us to lose patent rights in the relevant jurisdiction(s);<br>
&#160; </li>

<li>subjecting us to litigation, or otherwise preventing us from commercializing potential products in the relevant jurisdiction(s);<br>
&#160; </li>

<li>requiring us to obtain licenses to the disputed patents;<br>
&#160; </li>

<li>forcing us to cease using the disputed technology; or<br>
&#160; </li>

<li>requiring us to develop or obtain alternative technologies. </li>
</ul>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">Furthermore, if such challenges to our patent rights are not resolved promptly in our favor, our existing business relationships may be jeopardized and we could be delayed or prevented from entering into new collaborations or from commercializing certain products, which could materially harm our business. </font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">If we fail to meet our obligations under license agreements, we may lose our rights to key technologies on which our business depends. </font></font></font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">Our business depends on several critical technologies that are based in part on patents licensed from third parties, including the rights we licensed from Angiochem in connection with our exclusive worldwide license we entered into in December 2010. Those third-party license agreements impose obligations on us, such as payment obligations and obligations to diligently pursue development of commercial products under the licensed patents. If a licensor believes that we have failed to meet our obligations under a license agreement, the licensor could seek to limit or terminate our license rights, which could lead to costly and time-consuming litigation and, potentially, a loss of the licensed rights. During the period of any such litigation our ability to carry out the development and commercialization of potential products could be significantly and negatively affected. If our license rights were restricted or ultima
tely lost, our ability to continue our business based on the affected technology would be severely adversely affected. </font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">We may be subject to litigation that will be costly to defend or pursue and uncertain in its outcome. </font></font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Our business may bring us into conflict with our licensees, licensors, or others with whom we have contractual or other business relationships, or with our competitors or others whose interests differ from ours. If we are unable to resolve those conflicts on terms that are satisfactory to all parties, we may become involved in litigation brought by or against us. That litigation is likely to be expensive and may require a significant amount of management&#8217;s time and attention, at the expense of other aspects of our business. The outcome of litigation is always uncertain, and in some cases could include judgments against us that require us to pay damages, enjoin us from certain activities, or otherwise affect our legal or contractual rights, which could have a significant adverse effect on our business. </font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">We may be subject to infringement claims that are costly to defend, and which may limit our ability to use disputed technologies and prevent us from pursuing research and development or commercialization of potential products. </font></font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Our commercial success depends significantly on our ability to operate without infringing patents and the proprietary rights of others. Our technologies may infringe the patents or proprietary rights of others. In addition, we may become aware of discoveries and technology controlled by third parties that are advantageous to our programs. In the event our technologies infringe the rights of others or we require the use of discoveries and technology controlled by third parties, we may be prevented from pursuing research, development or commercialization of potential products or may be required to obtain licenses to those patents or other proprietary rights or develop or obtain alternative technologies. We have obtained licenses from several universities and companies for technologies that we anticipate incorporating into our potential products, and we initia
te negotiation for licenses to other technologies as the need or opportunity arises. We <font size="2" style="FONT-FAMILY: Times New Roman">may not be able to obtain a license to patented technology on commercially favorable terms, or at all. If we do not obtain a necessary license, we may need to redesign our technologies or obtain rights to alternate technologies, the research and adoption of which could cause delays in product development. In cases where we are unable to license necessary technologies, we could be prevented from developing certain potential products. Our failure to obtain alternative technologies or a license to any technology that we may require to research, develop or commercialize our product candidates would significantly and negatively affect our business. </font></font></div>

<div><font size="2" style="FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">10 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Much of the information and know-how that is critical to our business is not patentable and we may not be able to prevent others from obtaining this information and establishing competitive enterprises. </font></font></font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">We sometimes rely on trade secrets to protect our proprietary technology, especially in circumstances in which we believe patent protection is not appropriate or available. We attempt to protect our proprietary technology in part by confidentiality agreements with our employees, consultants, collaborators and contractors. We cannot assure you that these agreements will not be breached, that we would have adequate remedies for any breach, or that our trade secrets will not otherwise become known or be independently discovered by competitors, any of which would harm our business significantly. </font></div>

<div>&#160;</div>

<div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">RISKS RELATED TO OUR RELATIONSHIPS WITH THIRD PARTIES </font></font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">We depend on other parties to help us develop, manufacture and test our product candidates, and our ability to develop and commercialize potential products may be impaired or delayed if collaborations are unsuccessful. </font></font></font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">Our strategy for the development, clinical testing and commercialization of our product candidates requires that we enter into collaborations with corporate partners, licensors, licensees and others. We are dependent upon the subsequent success of these other parties in performing their respective responsibilities and the continued cooperation of our partners. By way of examples: Merck is developing cancer vaccines targeted to telomerase other than dendritic cell-based vaccines; Sienna is developing cancer diagnostics using our telomerase technology; and GE Healthcare UK Limited is developing cell-based assays using cells derived from our hESCs. Our collaborators may not cooperate with us or perform their obligations under our agreements with them. We cannot control the amount and timing of our collaborators&#8217; resources that will be devoted to activities related to our collaborative agreements with them. Our c
ollaborators may choose to pursue existing or alternative technologies in preference to those being developed in collaboration with us. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Under agreements with other parties, we may rely significantly on them to, among other activities:</font></div>

<ul style="FONT-SIZE: 10pt">
<li>conduct research and development activities in conjunction with us;<br>
&#160; </li>

<li>design and conduct advanced clinical trials in the event that we reach clinical trials;<br>
&#160; </li>

<li>fund research and development activities with us;<br>
&#160; </li>

<li>manage and license certain patent rights;<br>
&#160; </li>

<li>pay us fees upon the achievement of milestones; and<br>
&#160; </li>

<li>market with us any commercial products that result from our collaborations. </li>
</ul>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>The development and commercialization of potential products will be delayed if collaborators or other partners fail to conduct these activities in a timely manner or at all. In addition, our collaborators could terminate their agreements with us and we may not receive any development or milestone payments. If we do not achieve milestones set forth in the agreements, or if our collaborators breach or terminate their collaborative agreements with us, our business may be materially harmed.</font></div>

<div>&#160;</div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">11 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman"><font size="2" style="FONT-FAMILY: Times New Roman">We also rely on other companies for certain process development, manufacturing or other technical scientific work, especially with respect to our imetelstat, GRN1005 (formerly ANG1005), GRNVAC1, </font>GRNOPC1 and GRNCM1 programs. We have contracts with these companies that specify the work to be done and results to be achieved, but we do not have direct control over their personnel or operations. If these companies do not perform the work which they were assigned, our ability to develop or manufacture our product candidates could be significantly harmed.</font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Our reliance on the activities of our consultants, research institutions, and scientific contractors, whose activities are not wholly within our control, may lead to delays in development of our product candidates. </font></font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>We rely extensively upon and have relationships with scientific consultants at academic and other institutions, some of whom conduct research at our request, and other consultants who assist us in formulating our research and development and clinical strategy or other matters. These consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. We have limited control over the activities of these consultants and, except as otherwise required by our collaboration and consulting agreements, can expect only limited amounts of their time to be dedicated to our activities. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>In addition, we have formed research collaborations with many academic and other research institutions throughout the world. These research facilities may have commitments to other commercial and noncommercial entities. We have limited control over the operations of these laboratories and can expect only limited amounts of their time to be dedicated to our research goals. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>If any of these third parties are unable or refuse to contribute to projects on which we need their help, our ability to generate advances in our technologies and develop our product candidates could be significantly harmed. </font></div>

<div>&#160;</div>

<div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">RISKS RELATED TO COMPETITIVE FACTORS </font></font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">The loss of key personnel could slow our ability to conduct research and develop product candidates. </font></font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Our future success depends to a significant extent on the skills, experience and efforts of our executive officers and key members of our scientific staff. We face intense competition for qualified individuals from numerous pharmaceutical, biopharmaceutical and biotechnology companies, as well as academic and other research institutions. We may be unable to retain our current personnel or attract or assimilate other highly qualified management and scientific personnel in the future on acceptable terms. The loss of any or all of these individuals could harm our business and might significantly delay or prevent the achievement of research, development or business objectives. </font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Our product candidates are likely to be expensive to manufacture, and they may not be profitable if we are unable to significantly reduce the costs to manufacture them. </font></font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Our telomerase inhibitor compound, imetelstat, our telomerase cancer vaccine, GRNVAC1, and our hESC-based products are likely to be more expensive to manufacture than most other treatments currently on the market today, and the same is likely to be true of peptide products able to cross the BBB, including GRN1005 (formerly ANG1005). Oligonucleotides are relatively large molecules with complex chemistry, and the cost of manufacturing an oligonucleotide like imetelstat is greater than the cost of making most small-molecule drugs. Our present manufacturing processes are conducted at a modest scale and we hope to substantially reduce manufacturing costs through process improvements, as well as through scale increases. If we are not able to do so, however, and, depending on the pricing of the potential product, the profit margin on the telomerase inhibitor may b
e significantly less than that of most drugs on the market today. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3">&#160;&#160;&#160;&#160; </font>GRNVAC1 is an autologous therapy that is produced from a patient&#8217;s blood using a unique process that generates highly activated dendritic cells that contain RNA coding for the protein component of telomerase. If we are unable to scalably produce dendritic cells at a lower manufacturing cost, the cost of GRNVAC1 may reduce the affordability of the therapy for patients and reduce our potential profitability. </font></div>

<div>&#160;</div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">12 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman"><font size="2" style="FONT-FAMILY: Times New Roman">GRN1005 (formerly ANG1005) is a novel taxane derivative that is designed to cross the BBB by receptor-mediated transcytosis. The present manufacturing processes for GRN1005 (formerly ANG1005) are conducted at a small scale and we hope to substantially reduce manufacturing costs through process improvements, as well as through scale increases. If we are not able to do so, however, and, depending on the pricing of the potential product, the profit margin on GRN1005 (formerly ANG1005) may be significantly less than that of most drugs on the market today. </font></font></div>

<div><font size="2" style="FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; Our manufacturing processes for differentiated cells from hESCs are conducted at a small scale and at a high cost per unit measure. The cell-based therapies we are developing based on hESCs will probably require large quantities of cells. We continue to develop processes to scale up production of the cells in a cost-effective way. We may not be able to charge a high enough price for any cell therapy product we develop, even if it is safe and effective, to make a profit. If we are unable to realize significant profits from our potential product candidates, our business would be materially harmed.</font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Some of our competitors may develop technologies that are superior to or more cost-effective than ours, which may impact the commercial viability of our technologies and which may significantly damage our ability to sustain operations. </font></font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>The pharmaceutical and biotechnology industries are intensely competitive. Other pharmaceutical and biotechnology companies and research organizations currently engage in or have in the past engaged in efforts related to the biological mechanisms that are the focus of our programs in oncology and human embryonic stem cell therapies, including the study of telomeres, telomerase, receptor-targeting peptides crossing the BBB and hESCs. In addition, other products and therapies that could compete directly with the product candidates that we are seeking to develop and market currently exist or are being developed by pharmaceutical and biopharmaceutical companies and by academic and other research organizations. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Many companies are developing alternative therapies to treat cancer and, in this regard, are competitors of ours. According to public data from the FDA and NIH, there are more than 200 approved anti-cancer products on the market in the United States, and several thousand in clinical development. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Many of the pharmaceutical companies developing and marketing these competing products (including GlaxoSmithKline, Bristol-Myers Squibb Company and Novartis AG, among others) have significantly greater financial resources and expertise than we do in: </font></div>

<ul style="FONT-SIZE: 10pt">
<li><font size="2" style="FONT-FAMILY: Times New Roman">research and development;<br>
&#160; </font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">manufacturing;<br>
&#160; </font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">preclinical and clinical testing;<br>
&#160; </font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">obtaining regulatory approvals; and<br>
&#160; </font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">marketing and distribution.</font> </li>
</ul>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">Smaller companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Academic institutions, government agencies and other public and private research organizations may also conduct research, seek patent protection and establish collaborative arrangements for research, clinical development and marketing of products similar to ours. These companies and institutions compete with us in recruiting and retaining qualified scientific and management personnel as well as in acquiring technologies complementary to our programs. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>In addition to the above factors, we expect to face competition in the following areas: </font></div>

<ul style="FONT-SIZE: 10pt">
<li><font size="2" style="FONT-FAMILY: Times New Roman">product efficacy and safety;<br>
&#160; </font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">the timing and scope of regulatory consents;<br>
&#160; </font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">availability of resources;<br>
&#160; </font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">reimbursement coverage;<br>
&#160; </font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">price; and<br>
&#160; </font> </li>

<li><font size="2" style="FONT-FAMILY: Times New Roman">patent position, including potentially dominant patent positions of others.</font> </li>
</ul>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">13 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">As a result of the foregoing, our competitors may develop more effective or more affordable products, or achieve earlier patent protection or product commercialization than we do. Most significantly, competitive products may render any product candidates that we develop obsolete, which would negatively impact our business and ability to sustain operations. </font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">To be successful, our product candidates must be accepted by the health care community, which can be very slow to adopt or unreceptive to new technologies and products. </font></font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Our product candidates and those developed by our collaborators, if approved for marketing, may not achieve market acceptance since hospitals, physicians, patients or the medical community in general may decide not to accept and utilize these products. The product candidates that we are attempting to develop represent substantial departures from established treatment methods and will compete with a number of conventional drugs and therapies manufactured and marketed by major pharmaceutical companies. The degree of market acceptance of any of our developed potential products will depend on a number of factors, including: </font></div>

<ul style="FONT-SIZE: 10pt">
<li><font size="2" style="FONT-FAMILY: Times New Roman">our establishment and demonstration to the medical community of the clinical efficacy and safety of our product candidates;<br>
&#160;</font> </li>

<li>our ability to create products that are superior to alternatives currently on the market;<br>
&#160; </li>

<li>our ability to establish in the medical community the potential advantage of our treatments over alternative treatment methods; and<br>
&#160;&#160; </li>

<li>reimbursement policies of government and third-party payors. </li>
</ul>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">If the health care community does not accept our potential products for any of the foregoing reasons, or for any other reason, our business would be materially harmed. </font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">If we fail to obtain acceptable prices or adequate reimbursement for our product candidates, the use of our potential products could be severely limited. </font></font></font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">Our ability to successfully commercialize our product candidates will depend significantly on our ability to obtain acceptable prices and the availability of reimbursement to the patient from third-party payors. In March 2010, President Obama signed the Patient Protection and Affordability Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively, the PPACA) into law. Focused on expanding healthcare coverage to millions of uninsured Americans and reducing the rate of increase in healthcare costs, the PPACA contains numerous initiatives that impact the pharmaceutical industry. These include, among other things: </font></div>

<ul style="FONT-SIZE: 10pt">
<li><font size="2" style="FONT-FAMILY: Times New Roman">increasing existing price rebates in federally funded health care programs;</font> <br>
&#160; </li>

<li>expanding rebates, or other pharmaceutical company discounts, into new programs;<br>
&#160; </li>

<li>imposing a new non-deductible excise tax on sales of certain prescription pharmaceutical products by prescription drug manufacturers and importers;<br>
&#160; </li>

<li>reducing incentives for employer-sponsored health care;<br>
&#160; </li>

<li>creating an independent commission to propose changes to Medicare with a particular focus on the cost of biopharmaceuticals in Medicare Part D;<br>
&#160; </li>

<li>providing a government-run public option with biopharmaceutical price-setting capabilities;<br>
&#160; </li>

<li>allowing the Secretary of Health and Human Services to negotiate drug prices within Medicare Part D directly with pharmaceutical manufacturers;<br>
&#160; </li>

<li>reducing the number of years of data exclusivity for innovative biological products potentially leading to earlier biosimilar competition; and<br>
&#160; </li>

<li>increasing oversight by the FDA of pharmaceutical research and development processes and commercialization tactics. </li>
</ul>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">14 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">While the PPACA may increase the number of patients who have insurance coverage for our product candidates, its cost containment measures could also adversely affect reimbursement for our potential products. Cost control initiatives could decrease the price that we receive for any product candidate we may develop in the future. If our potential products are not considered cost-effective or if we fail to generate adequate third-party reimbursement for the users of our potential products and treatments, then we may be unable to maintain price levels sufficient to realize an appropriate return on our investment for potential products currently in development, which could have an adverse impact on our business. </font></div>

<div>&#160;</div>

<div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">RISKS RELATED TO ENVIRONMENTAL AND PRODUCT LIABILITY </font></font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Our activities involve hazardous materials, and improper handling of these materials by our employees or agents could expose us to significant legal and financial penalties. </font></font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Our research and development activities involve the controlled use of hazardous materials, chemicals and various radioactive compounds. As a consequence, we are subject to numerous environmental and safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of biohazardous materials. We may be required to incur significant costs to comply with current or future environmental laws and regulations and may be adversely affected by the cost of compliance with these laws and regulations. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Although we believe that our safety procedures for using, handling, storing and disposing of hazardous materials comply with the standards prescribed by state and federal regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. In the event of such an accident, state or federal authorities could curtail our use of these materials and we could be liable for any civil damages that result, the cost of which could be substantial. Further, any failure by us to control the use, disposal, removal or storage, or to adequately restrict the discharge, or assist in the clean up, of hazardous chemicals or hazardous, infectious or toxic substances could subject us to significant liabilities, including joint and several liability under certain statutes. Any such liability could exceed our resources and could have a material a
dverse effect on our business, financial condition and results of operations. Additionally, an accident could damage our research and manufacturing facilities and operations. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Additional federal, state and local laws and regulations affecting us may be adopted in the future. We may incur substantial costs to comply with these laws and regulations and substantial fines or penalties if we violate any of these laws or regulations, which would adversely affect our business. </font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">We may not be able to obtain or maintain sufficient insurance on commercially reasonable terms or with adequate coverage against potential liabilities in order to protect ourselves against product liability claims. </font></font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Our business exposes us to potential product liability risks that are inherent in the testing, manufacturing and marketing of human therapeutic and diagnostic products. We may become subject to product liability claims if the use of our potential products is alleged to have injured subjects or patients. This risk exists for product candidates tested in human clinical trials as well as potential products that are sold commercially. We currently have limited clinical trial liability insurance and we may not be able to maintain this type of insurance for any of our clinical trials. In addition, product liability insurance is becoming increasingly expensive. Being unable to obtain or maintain product liability insurance in the future on acceptable terms or with adequate coverage against potential liabilities could have a material adverse effect on our business.
 </font></div>

<div>&#160;</div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">15 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">RISKS RELATED TO OUR COMMON STOCK AND FINANCIAL REPORTING </font></font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Our stock price has historically been very volatile. </font></font></font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">Stock prices and trading volumes for many biopharmaceutical companies fluctuate widely for a number of reasons, including factors which may be unrelated to their businesses or results of operations such as media coverage, legislative and regulatory measures and the activities of various interest groups or organizations. This market volatility, as well as general domestic or international economic, market and political conditions, could materially and adversely affect the market price of our common stock and the return on your investment. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Historically, our stock price has been extremely volatile. Between January 1, 2000 and January 5, 2011, our stock has traded as high as $75.88 per share and as low as $1.41 per share. Between January 1, 2008 and January 5, 2011, the price has ranged between a high of $9.24 per share and a low of $1.95 per share. The significant market price fluctuations of our common stock are due to a variety of factors, including: </font></div>

<ul style="FONT-SIZE: 10pt">
<li><font size="2" style="FONT-FAMILY: Times New Roman">the demand in the market for our common stock;<br>
&#160;</font> </li>

<li>the experimental nature of our product candidates;<br>
&#160; </li>

<li>fluctuations in our operating results;<br>
&#160; </li>

<li>market conditions relating to the biopharmaceutical and pharmaceutical industries;<br>
&#160; </li>

<li>announcements of technological innovations, new commercial products, or clinical progress or lack thereof by us, our collaborative partners or our competitors;<br>
&#160; </li>

<li>announcements concerning regulatory developments, developments with respect to proprietary rights and our collaborations;<br>
&#160; </li>

<li>comments by securities analysts;<br>
&#160; </li>

<li>general market conditions;<br>
&#160; </li>

<li>political developments related to hESC research;<br>
&#160; </li>

<li>public concern with respect to our product candidates; and<br>
&#160; </li>

<li>the issuance of common stock to partners, vendors or to investors to raise additional capital. </li>
</ul>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">In addition, the stock market is subject to other factors outside our control that can cause extreme price and volume fluctuations. In the third and fourth quarters of 2008, as well as during 2009, broad distress in the financial markets and the economy have resulted in greatly increased market uncertainty and instability in both U.S. and international capital and credit markets. These conditions, combined with volatile oil prices, declining business and consumer confidence and increased unemployment have recently contributed to substantial market volatility, and if such market conditions persist, the price of our common stock may fluctuate or decline. Securities class action litigation has often been brought against companies, including many biotechnology companies, which experience volatility in the market price of their securities. </font><font size="2" style="FONT-FAMILY: Times New Roman">Litigation brought aga
inst us could result in substantial costs and a diversion of management&#8217;s attention and resources, which could adversely affect our business. </font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">We have been named a defendant in a purported securities class action lawsuit. This, and potential similar or related litigation, could result in substantial damages, divert management&#8217;s time and attention from our business, and have a material adverse effect on our results of operations.</font></font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>On December 21, 2010, a purported securities class action complaint was filed in the U.S. District Court for the Northern District of California, naming us and one of our executive officers as defendants. The lawsuit alleges that the defendants made materially false or misleading public statements&#160;regarding our financial condition&#160;in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended. The plaintiff seeks to represent a class of investors who purchased our common stock between July 30, 2010 <font size="2" style="FONT-FAMILY: Times New Roman">and December 6, 2010 and seeks damages, attorney<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8217;</font>s fees and other relief. As is typical in this type of litigation, it is possible that similar lawsuits may yet be filed in the same or other courts tha
t name the same or additional defendants.</font></font></div>

<div><font size="2" style="FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">16 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">We have not yet responded to the complaint, but we believe that the plaintiff&#8217;s allegations are without merit and we intend to vigorously defend against them. This lawsuit and any other related lawsuits are subject to inherent uncertainties, and the actual cost will depend upon many unknown factors. The outcome of the litigation is inherently uncertain. Monitoring and defending against legal actions is time-consuming for our management and detracts from our ability to fully focus our internal resources on our business activities. In addition, we may incur substantial legal fees and costs in connection with the litigation and we may not prevail. We are not currently able to estimate the possible cost to us from this matter, as the lawsuit is currently at an early stage and we cannot be certain of how long it may take to resolve the matter or the possible amount of damages (if any) that we may be required to pa
y. It is possible that we could incur a judgment or enter into a settlement of claims for monetary damages. A decision adverse to our interests in this lawsuit, or in similar or related litigation, could result in the payment of substantial damages by us, and could have a material adverse effect on our cash flow, results of operations and financial position. In addition, the inherent uncertainty of the currently-pending litigation could lead to more volatility in our stock price.</font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">The sale of a substantial number of shares may adversely affect the market price of our common stock. </font></font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>The sale of a substantial number of shares of our common stock in the public market, or the perception that such sales could occur, could significantly and negatively affect the market price of our common stock. As of January 5, 2011, we had 200,000,000 shares of common stock authorized for issuance and 127,915,896 shares of common stock outstanding. In addition, as of January 5, 2011, we have reserved for future issuance approximately 22,266,978 shares of common stock for our stock plans, potential milestone payments and outstanding warrants.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>In addition, we have issued common stock to certain parties, such as vendors and service providers, as payment for products and services. Under these arrangements, we typically agree to register the shares for resale soon after their issuance. We may continue to pay for certain goods and services in this manner, which would dilute your interest in us. Also, sales of the shares issued in this manner could negatively affect the market price of our common stock. </font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Our undesignated preferred stock may inhibit potential acquisition bids; this may adversely affect the market price&#160;of our common stock and the voting rights of holders of our common stock. </font></font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Our certificate of incorporation provides our Board of Directors with the authority to issue up to 3,000,000 shares of undesignated preferred stock and to determine or alter the rights, preferences, privileges and restrictions granted to or imported upon these shares without further vote or action by our stockholders. As of the date of this Registration Statement, 50,000 shares of preferred stock have been designated Series A Junior Participating Preferred Stock and the Board of Directors still has authority to designate and issue up to 2,950,000 shares of preferred stock in one or more classes or series. The issuance of shares of preferred stock may delay or prevent a change in control transaction without further action by our stockholders. As a result, the market price of our common stock may be adversely affected. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>In addition, if we issue preferred stock in the future that has preference over our common stock with respect to the payment of dividends or upon our liquidation, dissolution or winding up, or if we issue preferred stock with voting rights that dilute the voting power of our common stock, the rights of holders of our common stock or the market price of our common stock could be adversely affected. </font></div>

<div>&#160;</div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">17 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Provisions in our share purchase rights plan, charter and bylaws, and provisions of Delaware law, may inhibit potential acquisition bids for us, which may prevent holders of our common stock from benefiting from what they believe may be the positive aspects of acquisitions and takeovers. </font></font></font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">Our Board of Directors has adopted a share purchase rights plan, commonly referred to as a &#8220;poison pill.&#8221; This plan entitles existing stockholders to rights, including the right to purchase shares of common stock, in the event of an acquisition of 15% or more of our outstanding common stock. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Our share purchase rights plan could prevent stockholders from profiting from an increase in the market value of their shares as a result of a change of control of us by delaying or preventing a change of control. In addition, our Board of Directors has the authority, without further action by our stockholders, to issue additional shares of common stock, and to fix the rights and preferences of one or more series of preferred stock. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>In addition to our share purchase rights plan and the undesignated preferred stock, provisions of our charter documents and bylaws may make it substantially more difficult for a third party to acquire control of us and may prevent changes in our management, including provisions that: </font></div>

<ul style="FONT-SIZE: 10pt">
<li><font size="2" style="FONT-FAMILY: Times New Roman">prevent stockholders from taking actions by written consent;<br>
&#160;</font> </li>

<li>divide the Board of Directors into separate classes with terms of office that are structured to prevent all of the directors from being elected in any one year; and<br>
&#160; </li>

<li>set forth procedures for nominating directors and submitting proposals for consideration at stockholders&#8217; meetings. </li>
</ul>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">Provisions of Delaware law may also inhibit potential acquisition bids for us or prevent us from engaging in business combinations. In addition, we have severance agreements with several employees and a change of control severance plan which could require an acquiror to pay a higher price. Either collectively or individually, these provisions may prevent holders of our common stock from benefiting from what they may believe are the positive aspects of acquisitions and takeovers, including the potential realization of a higher rate of return on their investment from these types of transactions.</font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">We do not intend to pay cash dividends on our common stock in the foreseeable future. </font></font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>We do not anticipate paying cash dividends on our common stock in the foreseeable future. Any payment of cash dividends will depend upon our financial condition, results of operations, capital requirements and other factors and will be at the discretion of the Board of Directors. Furthermore, we may incur additional indebtedness that may severely restrict or prohibit the payment of dividends. </font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Failure to achieve and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on our business and stock price. </font></font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>Section 404 of the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act) requires that we establish and maintain an adequate internal control structure and procedures for financial reporting. Our annual report on Form 10-K must contain an assessment by management of the effectiveness of our internal control over financial reporting and must include disclosure of any material weaknesses in internal control over financial reporting that we have identified. In addition, our independent registered public accounting firm must annually provide an opinion on the effectiveness of our internal control over financial reporting. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>The requirements of Section 404 of the Sarbanes-Oxley Act are ongoing and also apply to future years. We expect that our internal control over financial reporting will continue to evolve as our business develops. Although we are committed to continue to improve our internal control processes and we will continue to diligently and vigorously review our internal control over financial reporting in order to ensure compliance with Section 404 requirements, any control system, regardless of how well designed, operated and evaluated, can provide only reasonable, not absolute, assurance that its objectives will be met. Therefore, we cannot be certain that in the future material weaknesses or significant deficiencies will not <font size="2" style="FONT-FAMILY: Times New Roman">exist or otherwise be discovered. If material weaknesses or other significant deficiencie
s occur, these weaknesses or deficiencies could result in misstatements of our results of operations, restatements of our consolidated financial statements, a decline in our stock price, or other material adverse effects on our business, reputation, results of operations, financial condition or liquidity. </font></font></div>

<div><font size="2" style="FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">18 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">FORWARD-LOOKING STATEMENTS </font></font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">This prospectus and the documents incorporated by reference in this prospectus include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and projections about future events. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. These forward-looking statements are generally identified by words such as &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;may&#8221; and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forwa
rd-looking statements. Forward-looking statements include, but are not necessarily limited to, those relating to: </font></div>

<ul style="FONT-SIZE: 10pt">
<li><font size="2" style="FONT-FAMILY: Times New Roman">future product research and development activities, including the scope, timing, initiation and completion of clinical trials, and status of product development;<br>
&#160;</font> </li>

<li>the size and timing of expenditures and whether there are unanticipated expenditures;<br>
&#160; </li>

<li>our requirements for additional capital;<br>
&#160; </li>

<li>plans for regulatory filings;<br>
&#160; </li>

<li>the timing of regulatory submissions and the timing, scope and anticipated outcome of related regulatory actions;<br>
&#160; </li>

<li>our current and potential future collaborators&#8217; ability to market, commercialize and achieve market acceptance for our product candidates or products that we may develop;<br>
&#160; </li>

<li>our ability to maintain our collaborative arrangements and to establish and maintain potential new collaborative arrangements for the development and commercialization of our product candidates;<br>
&#160; </li>

<li>our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;<br>
&#160; </li>

<li>the implementation of our corporate strategy;<br>
&#160; </li>

<li>the timing and amounts of any royalty or milestone payments to Angiochem pursuant to our exclusive license agreement with them;<br>
&#160; </li>

<li>our estimates regarding the sufficiency of our cash resources; and<br>
&#160; </li>

<li>future financial performance. </li>
</ul>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">Any or all of our forward-looking statements in this prospectus and the documents we have filed with the SEC that are incorporated by reference in this prospectus may turn out to be wrong. They can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Many factors mentioned in our discussion in this prospectus will be important in determining future results. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font size="3" style="FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160; </font>We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. We advise you to consult the cautionary discussion of risks and uncertainties under the section captioned &#8220;Risk Factors&#8221; contained elsewhere in this prospectus in its entirety. These are factors that we think could cause our actual results to differ materially from expected results. Other factors besides those listed could also adversely affect us. Given these risks, uncertainties and other important factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date such forward-looking statements are made. This discussion is provided as permitted by the Private Securities Litigation Reform
 Act of 1995. </font></div>

<div>&#160;</div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">19&#160;</font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">USE OF PROCEEDS </font></font></div>

<div>&#160;</div>

<div align="left">&#160;&#160;&#160;&#160; <font size="2" style="FONT-FAMILY: Times New Roman">We are filing the registration statement of which this prospectus is a part under our contractual obligations to the holder named in the section entitled &#8220;Selling Stockholder.&#8221; We will not receive any of the proceeds from resale of these shares of common stock by the selling stockholder. The selling stockholder will pay any underwriting discounts and commissions and expenses incurred by the selling stockholder for brokerage, accounting, tax or legal services or any other expenses incurred by the selling stockholder in disposing of the shares. We will bear all other costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus, including, without limitation, all registration and filing fees, and fees and expenses of our counsel and our independent registered public accounting firm.</font></div>

<div>&#160;</div>

<div align="center"><font size="2" style="FONT-FAMILY: Times New Roman">20 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<!-- part C-->
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">SELLING STOCKHOLDER </font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;The following table sets forth the name of the selling stockholder, the number of shares of common stock owned beneficially by the selling stockholder as of January 5, 2011, the number of shares which may be offered pursuant to this prospectus and the number of shares to be owned by the selling stockholder after this offering. In the aggregate, the selling stockholder may sell up to 5,261,144</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman"> </font></font><font size="2" style="FONT-FAMILY: Times New Roman">shares of our common stock pursuant to this prospectus. Since the selling stockholder may offer all, some or none of its common stock, no definitive estimate as to the number of shares thereof that will be held by the selling stockholder after the offering can be provided. Information concerning the selling
 stockholder may change from time to time and, when necessary, any changed information will be set forth in a prospectus supplement to this prospectus. We are registering the above-referenced shares to permit the selling stockholder and its pledgees, donees, transferees or other successors-in-interest that receive its shares after the date of this prospectus to resell or otherwise dispose of the shares in the manner contemplated under &#8220;Plan of Distribution&#8221; below. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;To our knowledge Angiochem has sole voting and investment power with respect to all shares of common stock beneficially owned by it. This information is based upon information provided by the selling stockholder. </font></div>

<div>&#160;</div>

<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse; ">
<tr valign="bottom">
<td nowrap width="84%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="1%" style="TEXT-ALIGN: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </td>
<td nowrap width="3%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="1%" style="TEXT-ALIGN: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </td>
<td nowrap width="3%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">Maximum Number of</font></font></td>
<td nowrap width="1%" style="TEXT-ALIGN: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </td>
<td nowrap width="3%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="1%" style="TEXT-ALIGN: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160; </td>
<td nowrap width="2%" style="TEXT-ALIGN: center">&#160;</td>
</tr><tr valign="bottom">
<td nowrap width="84%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="1%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="3%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">Total</font></font></td>
<td nowrap width="1%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="3%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">Shares Available</font></font></td>
<td nowrap width="1%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="3%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">Shares Owned</font></font></td>
<td nowrap width="1%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="2%" style="TEXT-ALIGN: center">&#160;</td>
</tr><tr valign="bottom">
<td nowrap width="84%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="1%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="3%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">Number of</font></font></td>
<td nowrap width="1%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="3%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">Pursuant to this</font></font></td>
<td nowrap width="1%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="3%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">After Offering</font></font></td>
<td nowrap width="1%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="2%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">Percentage</font></font></td>
</tr><tr valign="bottom">
<td nowrap width="84%" style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">Name</font></font></td>
<td nowrap width="1%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="3%" style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">Shares Held</font></font></td>
<td nowrap width="1%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="3%" style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">Prospectus</font></font></td>
<td nowrap width="1%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="3%" style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">(1)</font></font></td>
<td nowrap width="1%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="2%" style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">(2)</font></font></td>
</tr><tr valign="bottom" bgcolor="silver">
<td align="left" nowrap width="84%"><font size="2" style="FONT-FAMILY: times new roman">Angiochem, Inc.</font></td>
<td nowrap width="1%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="3%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">5,261,144</font></td>
<td nowrap width="1%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="3%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">5,261,144</font></td>
<td nowrap width="1%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="3%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">0</font></td>
<td nowrap width="1%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="2%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">4.1%</font></td>
</tr></table>
</div>

____________________<br>
&#160;<br>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="">
<tr>
<td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(1)</font></td>
<td nowrap valign="top">&#160;&#160;&#160;&#160;&#160;</td>
<td valign="top" width="100%"><font size="2" style="FONT-FAMILY: times new roman">Assumes the sale of all shares of common stock offered by this prospectus.</font></td>
</tr><tr>
<td colspan="3" valign="top" width="100%">&#160;</td>
</tr><tr>
<td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(2)</font></td>
<td nowrap valign="top">&#160;</td>
<td valign="top" width="100%"><font size="2" style="FONT-FAMILY: times new roman">Based on 127,915,896 shares of common stock outstanding as of January 5, 2011.</font></td>
</tr></table>
</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">Relationship with Angiochem, Inc.</font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;On December 6, 2010, we entered into an exclusive license agreement with Angiochem, Inc. (Angiochem) that provides us with a worldwide exclusive license, with the right to grant sublicenses, to Angiochem&#8217;s proprietary peptide technology that facilitates the transfer of anti-cancer compounds across the blood-brain barrier to enable the treatment of primary brain cancers and cancers that have metastasized to the brain. As consideration for the license rights, we paid Angiochem an upfront payment of $7.5 million in cash and agreed to issue $27.5 million of shares of our common stock, subject to a maximum of 9,000,000 shares. On January 5, 2011, we issued to Angiochem 5,261,144 shares of our common stock, pursuant to a common stock purchase agreement representing the full payment of the $27.5 million of shares of our common stock. We are filing the registration st
atement of which this prospectus forms a part pursuant to our contractual obligations in the common stock purchase agreement.&#160;Angiochem has agreed with us not to dispose of the shares of common stock that we issued to them, or swap, hedge or sell short any shares of our common stock or securities convertible into or exercisable or exchangeable for our common stock until the later of: (a) the effectiveness of the registration statement to which this prospectus forms a part; and (b) the expiration of the sixty (60) day &#8220;lock-up&#8221; period that we and each of our executive officers and directors agreed to on December 7, 2010 pursuant to the terms of an underwriting agreement, subject to extension thereunder. Thereafter, sales by Angiochem are subject to certain monthly volume restrictions set forth in the common stock purchase agreement, subject to specified exceptions. </font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: Times New Roman">21 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">PLAN OF DISTRIBUTION </font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;We are registering a total of 5,261,144</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman"> </font></font><font size="2" style="FONT-FAMILY: Times New Roman">shares of our common stock on behalf of the selling stockholder. The selling stockholder and any of its pledgees, donees, transferees or other successors-in-interest may, from time to time, sell any or all of the shares of common stock offered hereby on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These sales may be in one or more transactions at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market prices, at varying prices determined at the time of sale or at&#160;negotiated prices. Subject to certain volume limitations on sales and other term
s agreed with the selling stockholder, the selling stockholder may use any one or more of the following methods when selling shares:</font></div>

<ul style="FONT-SIZE: 10pt">
<li>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">sales on the NASDAQ Global Select Market or any national securities exchange or U.S. inter-dealer system of a registered national securities association on which our common stock may be listed or quoted at the time of sale; </font></div>

<div>&#160;</div>
</li>

<li>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">sales in the over-the-counter market; </font></div>

<div>&#160;</div>
</li>

<li>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </font></div>

<div>&#160;</div>
</li>

<li>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; </font></div>

<div>&#160;</div>
</li>

<li>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </font></div>

<div>&#160;</div>
</li>

<li>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">an exchange distribution in accordance with the rules of the applicable exchange; </font></div>

<div>&#160;</div>
</li>

<li>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">privately negotiated transactions; </font></div>

<div>&#160;</div>
</li>

<li>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">transactions in which broker-dealers agree with the selling stockholder to sell a specified number of such shares at a stipulated price per share;<br>
&#160;</font></div>
</li>

<li>
<div align="left">through the writing of options, whether the options are listed on an option exchange or otherwise; <br>
&#160;</div>
</li>

<li>
<div align="left">through the settlement of short sales;</div>

<div>&#160;</div>
</li>

<li>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">a combination of any such methods of sale; and </font></div>

<div>&#160;</div>
</li>

<li>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">any other method permitted pursuant to applicable law.</font></div>
</li>
</ul>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;The selling stockholder may also sell the shares directly to market makers acting as principals and/or broker-dealers acting as agents for themselves or their customers. These broker-dealers may receive compensation in the form of discounts, concessions or commissions from the selling stockholder and/or the purchasers of shares for whom the broker-dealers may act as agents or to whom they sell as principal or both, which compensation as to a particular broker-dealer might be in excess of customary commissions. Market makers and block purchasers purchasing the shares will do so for their own account and at their own risk. It is possible that the selling stockholder will attempt to sell shares of common stock in block transactions to market makers or other purchasers at a price per share which may be below the then market price. The selling stockholder cannot assure t
hat all or any of the shares offered in this prospectus will be issued to, or sold by, the selling stockholder. The selling stockholder and any brokers, dealers or agents, upon effecting the sale of any of the shares offered in this prospectus, may be deemed &#8220;underwriters&#8221; as that term is defined under the Securities Act or the Exchange Act, or the rules and regulations under such acts.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;The selling stockholder, alternatively, may sell all or any part of the shares offered in this prospectus through an underwriter. In such event, any commissions received and any profit on the resale of the shares purchased by underwriters may be deemed to be underwriting commissions or discounts under the Securities Act. The maximum commission or discount to be received by any member of the Financial Industry Regulatory Authority or independent broker-dealer will not be greater than 8% of the initial gross proceeds from the sale of any security being sold. To our knowledge, the selling stockholder has not entered into any agreement with a prospective underwriter and we cannot assure you that any such agreement will be entered into. If the selling stockholder enters into this type of an agreement or agreements, the relevant details will be set forth in a supplement o
r revision to this prospectus.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;The selling stockholder and any other persons participating in the sale or distribution of the shares will be subject to applicable provisions of the Exchange Act and the rules and regulations under the Exchange Act, including, without limitation, Regulation M. These provisions may restrict certain activities of, and limit the timing of purchases and sales of any of the shares by, the selling stockholder or any other person.</font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: Times New Roman">22 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">Furthermore, under Regulation M, persons engaged in a distribution of securities are prohibited from simultaneously engaging in market making and certain other activities with respect to the securities for a specified period of time prior to the commencement of the distributions, subject to specified exceptions or exemptions. All of these limitations may affect the marketability of the shares.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;The selling stockholder also may sell all or a portion of its shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided it meets the criteria and conforms to the requirements of Rule 144. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;The selling stockholder may from time to time pledge or grant a security interest in some or all of the shares of common stock owned by it and, if it defaults in the performance of its secured obligations, the pledgees or secured parties may offer and sell shares of common stock from time to time under this prospectus, or under a supplement or amendment to this prospectus. The selling stockholder also may transfer the shares of common stock in other circumstances, in which case the transferees, assignees or successors in interest will be the selling beneficial owners for purposes of this prospectus. </font></div>

<div align="left"><font size="2">&#160;</font></div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;&#160;</font>In connection with the sale of the common stock or interests therein the selling stockholder may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholder may also sell shares of the common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholder may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institut
ion may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</font></div>

<div align="left"><font size="2">&#160;</font></div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;&#160;</font>The selling stockholder may enter into derivative transactions or forward sale agreements on shares of common stock with third parties. In such event, the selling stockholder may pledge the shares underlying such transactions to the counterparties under such agreements, to secure the selling stockholder<font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8217;</font>s delivery obligation. The counterparties or third parties may borrow shares of common stock from us, the selling stockholder or third parties and sell such shares in a public offering.&#160; This prospectus may be delivered in conjunction with such sales. Upon settlement of such transactions, the selling stockholder may deliver shares of common stock to the counterparties that, in turn, the counterparties may deliver to the selling stockholder or third parties, as the case may be, to close out 
the open borrowings of common stock. The counterparty in such transactions will be an underwriter and will be identified in the applicable prospectus supplement.</font></div>

<div align="left"><font size="2">&#160;</font></div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;&#160;</font>All of the foregoing transactions are subject to the lock-up provisions and certain monthly volume limitations, in each case, as set forth in the common stock purchase agreement by which the shares were issued to the selling stockholder, as described under the caption &#8220;Selling Stockholder <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">&#8211;</font> Relationship with Angiochem, Inc.&#8221;</font><font size="2" style="FONT-FAMILY: Times New Roman"><br>
</font></div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font style="LETTER-SPACING: 3pt">&#160;&#160;&#160;&#160;</font>We have agreed with the selling stockholder to keep the registration statement of which this prospectus constitutes a part effective until the earlier of (a) the date that none of the shares covered by this registration statement are issued and outstanding, (b) the date that all of the shares covered by the registration statement have been sold pursuant to the registration statement, (c) the date that all shares covered by the registration statement have been otherwise transferred to persons who may trade such shares without restriction under the Securities Act and we have delivered a new certificate of other evidence of ownership for such shares not bearing a restrictive legend and (d) such time as all of the shares covered by the registration statement may be disposed of without limitation, except as otherwise set forth in the common stock purchase agreement, pursuant to Ru
le 144 of the Securities Act or any similar provision then in effect under the Securities Act.</font></div>
</div>

<div align="left"><font size="2">&#160;</font></div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;&#160;</font>We have agreed to indemnify the selling stockholder against certain civil liabilities, including certain liabilities arising under the Securities Act, and the selling stockholder will be entitled to contribution from us in connection with such liabilities.</font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">VALIDITY OF THE SECURITIES </font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;Latham &amp; Watkins LLP, Menlo Park, California, will pass on the validity of the issuance of the shares of common stock offered by this prospectus. </font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">EXPERTS </font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;The consolidated financial statements of Geron Corporation appearing in Geron&#8217;s Annual Report on Form 10-K for the year ended December 31, 2009, and the effectiveness of internal control over financial reporting as of December 31, 2009, have been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as set forth in their reports thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such reports given on the authority of such firm as experts in accounting and auditing. </font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">MATERIAL CHANGES </font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;As of the date of this prospectus, there have been no material changes in our affairs since December 31, 2009, which have not been described in subsequent reports on Form 10-Q or Form 8-K. See also the section&#160;entitled &#8220;Risks Related to Our Common Stock and Financial Reporting&#8221; under the heading &#8220;Risk Factors&#8221; contained elsewhere in this prospectus.</font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">WHERE YOU CAN FIND MORE INFORMATION </font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;We file annual, quarterly and special reports, proxy statements and other information with the SEC. We make available free of charge on or through our Internet website our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and all amendments to those reports as soon as reasonably practicable after they are electronically filed with, or furnished to, the Securities and Exchange Commission. Our Internet website address is www.geron.com. You may read and copy any document we file at the SEC&#8217;s public reference room located at Room 1580, 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. Our SEC filings are also available to the public at the SEC&#8217;s website at http://www.sec.gov. </font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: Times New Roman">23 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">DOCUMENTS WE HAVE INCORPORATED BY REFERENCE </font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;The SEC allows us to &#8220;incorporate by reference&#8221; the information we file with them which means that we can disclose important information to you by referring you to those documents instead of having to repeat the information in this prospectus. The information incorporated by reference is considered to be part of this prospectus, and later information that we file with the SEC will automatically update and supersede this information. We incorporate by reference the documents listed below and any future information filed (rather than furnished) with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act between the date of this prospectus and the date the selling stockholder sells all of the shares, provided, however, that we are not incorporating any information furnished under any of Item 2.02 or Item 7.01 of any current report on Form 8-K 
(and exhibits filed on such form that are related to such items): </font></div>

<ul style="FONT-SIZE: 10pt">
<li>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">our annual report on Form 10-K for the fiscal year ended December 31, 2009, filed with the SEC on February 26, 2010; </font></div>

<div>&#160;</div>
</li>

<li>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">the portions specifically incorporated by reference into our annual report on Form 10-K for the year ended December 31, 2009 from our definitive proxy statement on schedule 14A, filed with the SEC on March 29, 2010; </font></div>

<div>&#160;</div>
</li>

<li>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">our quarterly report on Form 10-Q for the quarter ended March 31, 2010, filed with the SEC on April 30, 2010; </font></div>

<div>&#160;</div>
</li>

<li>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">our quarterly report on Form 10-Q for the quarter ended June 30, 2010, filed with the SEC on July 30, 2010; </font></div>

<div>&#160;</div>
</li>

<li>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">our quarterly report on Form 10-Q for the quarter ended September 30, 2010, filed with the SEC on October 29, 2010; </font></div>

<div>&#160;</div>
</li>

<li>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">our current reports on Form 8-K filed with the SEC on January 15, 2010, March 19, 2010, March 26, 2010, May 20, 2010, May 21, 2010, July 15, 2010, July 30, 2010, September 16, 2010, October 12, 2010, December 6, 2010, December 6, 2010 (as amended by the Form 8-K/A filed on December 7, 2010), December 7, 2010, December 10, 2010 and January 7, 2011; and </font></div>

<div>&#160;</div>
</li>

<li>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">the description of our common stock set forth in our registration statement on Form 8-A, filed with the SEC on June 13, 1996 (File No. 0-20859). </font></div>
</li>
</ul>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;All documents we file under Section 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits filed on such form that are related to such items) after the date of this registration statement and prior to the filing of a post-effective amendment that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be a part of it from the respective dates of filing those documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein modifies or supersedes that statement. Any st
atement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;We will furnish without charge to you, on written or oral request, a copy of any or all of the documents incorporated by reference, including exhibits to these documents. You should direct any requests for documents to David L. Greenwood, Chief Financial Officer, Geron Corporation, 230 Constitution Drive, Menlo Park, California 94025, telephone: (650) 473-7700. </font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: Times New Roman">24 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div style="TEXT-ALIGN: center">
<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>
</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">5,261,144 SHARES OF COMMON STOCK </font></font></div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">GERON CORPORATION </font></font></div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">PROSPECTUS </font></font></div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">, 2011 </font></font></div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div style="TEXT-ALIGN: center">&#160;</div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">YOU SHOULD RELY ONLY ON THE INFORMATION CONTAINED OR INCORPORATED BY REFERENCE IN THIS PROSPECTUS. WE HAVE NOT AUTHORIZED ANYONE TO PROVIDE YOU WITH DIFFERENT INFORMATION. YOU SHOULD NOT ASSUME THAT THE </font></font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">INFORMATION CONTAINED OR INCORPORATED BY REFERENCE IN THIS PROSPECTUS IS ACCURATE AS OF ANY DATE OTHER THAN THE DATE OF THIS PROSPECTUS. WE ARE NOT MAKING AN OFFER OF THESE SECURITIES IN ANY STATE WHERE THE OFFER IS NOT PERMITTED. </font></font></div>

<div align="left">&#160;</div>

<div align="left">&#160;</div>

<div align="left">&#160;</div>

<div align="left">&#160;</div>

<div align="left">&#160;</div>

<div align="left">&#160;</div>

<div align="left">&#160;</div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: Times New Roman">25 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">PART II </font></font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">INFORMATION NOT REQUIRED IN THE PROSPECTUS </font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">Item 14. Other Expenses of Issuance and Distribution. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;The following sets forth the costs and expenses, all of which shall be borne by the Registrant, in connection with the offering of the securities pursuant to this Registration Statement: </font></div>

<div>&#160;</div>

<div align="center">
<table border="0" cellpadding="0" cellspacing="0" width="50%" style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse; ">
<tr valign="bottom">
<td align="left" nowrap width="95%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">Registration Fee</font></td>
<td align="left" nowrap width="1%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">$&#160;&#160;&#160;&#160; </font></td>
<td align="right" nowrap width="2%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">3,231</font></td>
<td align="left" nowrap width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="left" nowrap width="1%" bgcolor="#c0c0c0">&#160;</td>
</tr><tr valign="bottom">
<td align="left" nowrap width="95%"><font size="2" style="FONT-FAMILY: times new roman">Accounting Fees and Expenses</font></td>
<td align="left" nowrap width="1%"><font size="2" style="FONT-FAMILY: times new roman">$</font></td>
<td align="right" nowrap width="2%"><font size="2" style="FONT-FAMILY: times new roman">10,000</font></td>
<td align="left" nowrap width="1%">&#160;</td>
<td align="left" nowrap width="1%"><font size="2" style="FONT-FAMILY: times new roman">*</font></td>
</tr><tr valign="bottom">
<td align="left" nowrap width="95%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">Legal Fees and Expenses</font></td>
<td align="left" nowrap width="1%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">$</font></td>
<td align="right" nowrap width="2%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">10,000</font></td>
<td align="left" nowrap width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="left" nowrap width="1%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">*</font></td>
</tr><tr valign="bottom">
<td align="left" nowrap width="95%"><font size="2" style="FONT-FAMILY: times new roman">Miscellaneous</font></td>
<td align="left" nowrap width="1%"><font size="2" style="FONT-FAMILY: times new roman">$</font></td>
<td align="right" nowrap width="2%"><font size="2" style="FONT-FAMILY: times new roman">1,500</font></td>
<td align="left" nowrap width="1%">&#160;</td>
<td align="left" nowrap width="1%"><font size="2" style="FONT-FAMILY: times new roman">*</font></td>
</tr><tr>
<td align="left" nowrap width="95%">&#160; </td>
<td align="left" nowrap width="1%">&#160;</td>
<td align="right" nowrap width="2%">&#160;</td>
<td align="left" nowrap width="1%">&#160;</td>
<td align="left" nowrap width="1%">&#160;</td>
</tr><tr valign="bottom">
<td align="left" nowrap width="95%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">Total</font></td>
<td align="left" nowrap width="1%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">$</font></td>
<td align="right" nowrap width="2%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">24,731</font></td>
<td align="left" nowrap width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="left" nowrap width="1%" bgcolor="#c0c0c0">&#160;</td>
</tr><tr>
<td align="left" nowrap width="95%">____________________</td>
<td align="left" nowrap width="1%">&#160;</td>
<td align="right" nowrap width="2%">&#160;</td>
<td align="left" nowrap width="1%">&#160;</td>
<td align="left" nowrap width="1%">&#160;</td>
</tr><tr>
<td align="left" nowrap width="95%">&#160; </td>
<td align="left" nowrap width="1%">&#160;</td>
<td align="right" nowrap width="2%">&#160;</td>
<td align="left" nowrap width="1%">&#160;</td>
<td align="left" nowrap width="1%">&#160;</td>
</tr><tr>
<td align="left" nowrap width="95%"><font size="1" style="FONT-FAMILY: times new roman">*&#160;&#160;&#160;&#160;&#160; Estimated </font></td>
<td align="left" nowrap width="1%">&#160;</td>
<td align="right" nowrap width="2%">&#160;</td>
<td align="left" nowrap width="1%">&#160;</td>
<td align="left" nowrap width="1%">&#160;</td>
</tr></table>
</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">Item 15. Indemnification of Directors and Officers.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;Section 145(a) of the General Corporation Law of the State of Delaware (the DGCL) provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if he or she acted in good faith and in a manner he or she reasonably believed to b
e in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no cause to believe his or her conduct was unlawful. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;Section 145(b) of the DGCL provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of corporation to procure a judgment in its favor by reason of the fact that such person acted in any of the capacities set forth above, against expenses actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if he or she acted under similar standards to those set forth above, except that no indemnification may be made in respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the court in which such action or suit was brought shall determine that despite the adjudication of liability, but in 
view of all the circumstances of the case, such person is fairly and reasonably entitled to be indemnified for such expenses which the court shall deem proper. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;Section 145 of the DGCL further provides that to the extent a director or officer of a corporation has been successful in the defense of any action, suit or proceeding referred to in subsection (a) and (b) or in the defense of any claim, issue or matter therein, he or she shall be indemnified against expenses actually and reasonably incurred by him or her in connection therewith; that indemnification provided for by Section 145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled; and that the corporation may purchase and maintain insurance on behalf of a director or officer of the corporation against any liability asserted against such officer or director and incurred by him or her in any such capacity or arising out of his or her status as such, whether or not the corporation would have the power to indemnify him or her 
against such liabilities under Section 145.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;As permitted by Section 102(b)(7) of the DGCL, our Certificate of Incorporation provides that a director shall not be liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director. However, this provision does not eliminate or limit the liability of a director for acts or omissions not in good faith or for breaching his or her duty of loyalty, engaging in intentional misconduct or knowingly violating the law, paying a dividend or approving a stock repurchase which was illegal, or obtaining an improper personal benefit. A provision of this type has no effect on the availability of equitable remedies, such as injunction or rescission, for breach of fiduciary duty. Our Certificate of Incorporation requires that directors and officers be indemnified to the maximum extent permitted by Delaware law.</font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: Times New Roman">II-1</font><font size="1" style="FONT-FAMILY: Times New Roman"> </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">Item 16. Exhibits. </font></div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;See Exhibit Index. </font></div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">Item 17. Undertakings.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;The undersigned registrant hereby undertakes:</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</font></div>

<div>&#160;</div>

<div style="PADDING-LEFT: 15pt" align="left"><font size="2" style="FONT-FAMILY: Times New Roman">(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</font></div>

<div>&#160;</div>

<div style="PADDING-LEFT: 15pt" align="left"><font size="2" style="FONT-FAMILY: Times New Roman">(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and</font></div>

<div>&#160;</div>

<div style="PADDING-LEFT: 15pt" align="left"><font size="2" style="FONT-FAMILY: Times New Roman">(iii) To include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement;</font></div>

<div>&#160;</div>

<div align="left"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;Provided, however, </font></font><font size="2" style="FONT-FAMILY: Times New Roman">that subparagraphs 1(i), 1(ii) and 1(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is a part of the registration statement.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time to be deemed the initial bona fide offering.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the regis
tration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: Times New Roman">II-2 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;(5) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&#8217;s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;The undersigned registrant hereby undertakes to deliver or cause to be delivered with the prospectus, to each person to whom the prospectus is sent or given, the latest annual report to security holders that is incorporated by reference in the prospectus and furnished pursuant to and meeting the requirements of Rule 14a-3 or Rule 14c-3 under the Securities Exchange Act of 1934; and, where interim financial information required to be presented by Article 3 of Regulation S-X is not set forth in the prospectus, to deliver, or cause to be delivered to each person to whom the prospectus is sent or given, the latest quarterly report that is specifically incorporated by reference in the prospectus to provide such interim financial information.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settle
d by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: Times New Roman">II-3 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">SIGNATURES </font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Menlo Park, State of California, on January 7, 2011. </font></div>

<div>&#160;</div>

<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse; ">
<tr valign="bottom">
<td align="left" nowrap width="57%">&#160;</td>
<td align="left" colspan="3" nowrap width="43%"><font size="2" style="FONT-FAMILY: times new roman">GERON CORPORATION</font></td>
</tr><tr>
<td align="left" nowrap width="57%">&#160;</td>
<td align="left" nowrap width="1%">&#160;</td>
<td align="left" colspan="2" nowrap width="42%">&#160;&#160; </td>
</tr><tr valign="bottom">
<td align="left" nowrap width="57%">&#160;</td>
<td align="left" nowrap width="1%"><font size="2" style="FONT-FAMILY: times new roman">By: &#160; </font></td>
<td align="left" nowrap width="21%" style="BORDER-BOTTOM: #000000 1pt solid"><font size="2" style="FONT-FAMILY: times new roman">/s/ David L. Greenwood</font></td>
<td align="left" nowrap width="21%">&#160;</td>
</tr><tr valign="bottom">
<td align="left" nowrap width="57%">&#160;</td>
<td align="left" nowrap width="1%">&#160;</td>
<td align="left" colspan="2" nowrap width="42%"><font size="2" style="FONT-FAMILY: times new roman">David L. Greenwood</font></td>
</tr><tr valign="bottom">
<td align="left" nowrap width="57%">&#160;</td>
<td align="left" nowrap width="1%">&#160;</td>
<td align="left" nowrap width="21%"><font size="2" style="FONT-FAMILY: times new roman">Executive Vice President and&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></td>
<td align="left" nowrap width="21%">&#160;</td>
</tr><tr valign="bottom">
<td width="57%" style="TEXT-ALIGN: center">&#160;</td>
<td width="1%" style="TEXT-ALIGN: center">&#160;</td>
<td align="left" colspan="2" width="42%"><font size="2" style="FONT-FAMILY: times new roman">Chief Financial Officer</font></td>
</tr></table>
</div>

<br>
<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">POWER OF ATTORNEY </font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;KNOW ALL BY THESE PERSONS PRESENT, that the persons whose signatures appear below do hereby constitute and appoint Thomas B. Okarma and David L. Greenwood, or any of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign a registration statement on Form S-3 and any or all amendments thereto (including without limitation any post-effective amendments thereto), and any registration statement for the same offering that is to be effective under Rule 462(b) of the Securities Act, and to file each of the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power a
nd authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises in order to effectuate the same as fully, to all intents and purposes, as they, he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. </font></div>

<div>&#160;</div>

<div align="left">
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse; ">
<tr valign="bottom">
<td nowrap width="5%" style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">Signature</font></font></td>
<td align="left" nowrap width="43%" style="PADDING-BOTTOM: 2px">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </td>
<td nowrap width="5%" style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">Title</font></font></td>
<td nowrap width="42%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </td>
<td nowrap width="5%" style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: times new roman">Date</font></font></td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; /s/ Thomas B. Okarma&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%"><font size="2" style="FONT-FAMILY: times new roman">Chief Executive Officer, President and</font></td>
<td nowrap width="42%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">January 7, 2011</font></td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">Thomas B. Okarma</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%"><font size="2" style="FONT-FAMILY: times new roman">Director (principal executive officer)</font></td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr>
<td nowrap width="5%" style="TEXT-ALIGN: center">&#160;</td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">/s/ David L. Greenwood</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%"><font size="2" style="FONT-FAMILY: times new roman">Executive Vice President and Chief</font></td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">David L. Greenwood</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%"><font size="2" style="FONT-FAMILY: times new roman">Financial Officer (principal financial</font></td>
<td nowrap width="42%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">January 7, 2011</font></td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="TEXT-ALIGN: center">&#160;</td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%"><font size="2" style="FONT-FAMILY: times new roman">officer)</font></td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr>
<td nowrap width="5%" style="TEXT-ALIGN: center">&#160;</td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">/s/ Olivia K. Bloom</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%"><font size="2" style="FONT-FAMILY: times new roman">Vice President and Chief Accounting</font></td>
<td nowrap width="42%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">January 7, 2011</font></td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">Olivia K. Bloom</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%"><font size="2" style="FONT-FAMILY: times new roman">Officer (principal accounting officer)</font></td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr>
<td nowrap width="5%" style="TEXT-ALIGN: center">&#160;</td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">/s/ Alexander E. Barkas</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%"><font size="2" style="FONT-FAMILY: times new roman">Director</font></td>
<td nowrap width="42%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">January 7, 2011</font></td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">Alexander E. Barkas</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr>
<td nowrap width="5%" style="TEXT-ALIGN: center">&#160;</td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">/s/ Karin Eastham</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%"><font size="2" style="FONT-FAMILY: times new roman">Director</font></td>
<td nowrap width="42%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">January 7, 2011</font></td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">Karin Eastham</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr>
<td nowrap width="5%" style="TEXT-ALIGN: center">&#160;</td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">/s/ Edward V. Fritzky</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%"><font size="2" style="FONT-FAMILY: times new roman">Director</font></td>
<td nowrap width="42%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">January 7, 2011</font></td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">Edward V. Fritzky</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr>
<td nowrap width="5%" style="TEXT-ALIGN: center">&#160;</td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">/s/ Thomas Hofstaetter</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%"><font size="2" style="FONT-FAMILY: times new roman">Director</font></td>
<td nowrap width="42%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">January 7, 2011</font></td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">Thomas Hofstaetter</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr>
<td nowrap width="5%" style="TEXT-ALIGN: center">&#160;</td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">/s/ Charles J. Homcy</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%"><font size="2" style="FONT-FAMILY: times new roman">Director</font></td>
<td nowrap width="42%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">January 7, 2011</font></td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">Charles J. Homcy</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr>
<td nowrap width="5%" style="TEXT-ALIGN: center">&#160;</td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">/s/ Hoyoung Huh</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%"><font size="2" style="FONT-FAMILY: times new roman">Director</font></td>
<td nowrap width="42%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">January 7, 2011</font></td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">Hoyoung Huh</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr>
<td nowrap width="5%" style="TEXT-ALIGN: center">&#160;</td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">/s/ Thomas D. Kiley</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%"><font size="2" style="FONT-FAMILY: times new roman">Director</font></td>
<td nowrap width="42%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">January 7, 2011</font></td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">Thomas D. Kiley</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr>
<td nowrap width="5%" style="TEXT-ALIGN: center">&#160;</td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="BORDER-BOTTOM: #000000 1pt solid; TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">/s/ Robert J. Spiegel</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%"><font size="2" style="FONT-FAMILY: times new roman">Director</font></td>
<td nowrap width="42%" style="TEXT-ALIGN: center">&#160;</td>
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">January 7, 2011</font></td>
</tr><tr valign="bottom">
<td nowrap width="5%" style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: times new roman">Robert J. Spiegel</font></td>
<td align="left" nowrap width="43%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
<td align="left" nowrap width="42%">&#160;</td>
<td align="left" nowrap width="5%">&#160;</td>
</tr></table>
</div>

<br>
<div style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: Times New Roman">S-1</font><font size="1" style="FONT-FAMILY: Times New Roman"> </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
<div id="PGBRK">
<div id="PN" style="PAGE-BREAK-BEFORE: always">&#160;</div>
</div>

<br>
<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">EXHIBIT INDEX </font></font></div>

<div>&#160;</div>

<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="LINE-HEIGHT: normal; BORDER-COLLAPSE: collapse; ">
<tr valign="bottom" style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse;">
<td align="left" colspan="3" nowrap valign="top" width="7%" style="BORDER-BOTTOM: #000000 1pt solid"><font size="2" style="FONT-FAMILY: times new roman">Exhibit No.</font></td>
<td align="left" nowrap valign="top" width="1%"><font size="2" style="FONT-FAMILY: times new roman">&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: #000000 1pt solid"><font size="2" style="FONT-FAMILY: times new roman">Description</font></td>
<td align="left" valign="top" width="90%">&#160;</td>
</tr><tr valign="bottom">
<td align="right" nowrap valign="top" width="5%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">3.1</font></td>
<td align="right" nowrap valign="top" width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="left" nowrap valign="top" width="1%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">(1)</font></td>
<td align="left" nowrap valign="top" width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="left" colspan="2" valign="top" width="91%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">Amended and Restated Certificate of Incorporation of the Registrant.</font></td>
</tr><tr valign="bottom">
<td align="right" nowrap valign="top" width="5%"><font size="2" style="FONT-FAMILY: times new roman">3.2</font></td>
<td align="right" nowrap valign="top" width="1%">&#160;</td>
<td align="left" nowrap valign="top" width="1%"><font size="2" style="FONT-FAMILY: times new roman">(2)</font></td>
<td align="left" nowrap valign="top" width="1%">&#160;</td>
<td align="left" colspan="2" valign="top" width="91%"><font size="2" style="FONT-FAMILY: times new roman">Certificate of Amendment of Restated Certificate of Incorporation of the Registrant.</font></td>
</tr><tr valign="bottom">
<td align="right" nowrap valign="top" width="5%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">3.3</font></td>
<td align="right" nowrap valign="top" width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="left" nowrap valign="top" width="1%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">(3)</font></td>
<td align="left" nowrap valign="top" width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="left" colspan="2" valign="top" width="91%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">Amended and Restated Bylaws of the Registrant</font></td>
</tr><tr valign="bottom">
<td align="right" nowrap valign="top" width="5%"><font size="2" style="FONT-FAMILY: times new roman">4.1</font></td>
<td align="right" nowrap valign="top" width="1%">&#160;</td>
<td align="left" nowrap valign="top" width="1%">&#160;</td>
<td align="left" nowrap valign="top" width="1%">&#160;</td>
<td align="left" colspan="2" valign="top" width="91%"><font size="2" style="FONT-FAMILY: times new roman">Reference is made to Exhibits 3.1, 3.2 and 3.3.</font></td>
</tr><tr valign="bottom">
<td align="right" nowrap valign="top" width="5%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">4.2</font></td>
<td align="right" nowrap valign="top" width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="left" nowrap valign="top" width="1%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">(4)</font></td>
<td align="left" nowrap valign="top" width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="left" colspan="2" valign="top" width="91%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">Form of Common Stock Certificate.</font></td>
</tr><tr valign="bottom">
<td align="right" nowrap valign="top" width="5%"><font size="2" style="FONT-FAMILY: times new roman">4.3</font></td>
<td align="right" nowrap valign="top" width="1%">&#160;</td>
<td align="left" nowrap valign="top" width="1%"><font size="2" style="FONT-FAMILY: times new roman">(5)</font></td>
<td align="left" nowrap valign="top" width="1%">&#160;</td>
<td align="left" colspan="2" valign="top" width="91%"><font size="2" style="FONT-FAMILY: times new roman">Rights Agreement, dated as of July 20, 2001, by and between the Registrant and U.S. Stock Transfer Corporation, as Rights Agent, which includes the form of Certification of Designations of the Series A Junior Participating Preferred Stock of the Registrant as Exhibit A, the form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Shares as Exhibit C.</font></td>
</tr><tr valign="bottom">
<td align="right" nowrap valign="top" width="5%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">5.1</font></td>
<td align="right" nowrap valign="top" width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="left" nowrap valign="top" width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="left" nowrap valign="top" width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="left" colspan="2" valign="top" width="91%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">Opinion of Latham &amp; Watkins LLP.</font></td>
</tr><tr valign="bottom">
<td align="right" nowrap valign="top" width="5%"><font size="2" style="FONT-FAMILY: times new roman">10.1</font></td>
<td align="right" nowrap valign="top" width="1%">&#160;</td>
<td align="left" nowrap valign="top" width="1%"><font size="2" style="FONT-FAMILY: times new roman">(6)</font></td>
<td align="left" nowrap valign="top" width="1%">&#160;</td>
<td align="left" colspan="2" valign="top" width="91%"><font size="2" style="FONT-FAMILY: times new roman">Common Stock Purchase Agreement dated as of January 5, 2011 by and between Registrant and Angiochem, Inc.</font></td>
</tr><tr valign="bottom">
<td align="right" nowrap valign="top" width="5%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">23.1</font></td>
<td align="right" nowrap valign="top" width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="left" nowrap valign="top" width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="left" nowrap valign="top" width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="left" colspan="2" valign="top" width="91%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">Consent of Latham &amp; Watkins LLP (included in Exhibit 5.1).</font></td>
</tr><tr valign="bottom">
<td align="right" nowrap valign="top" width="5%"><font size="2" style="FONT-FAMILY: times new roman">23.2</font></td>
<td align="right" nowrap valign="top" width="1%">&#160;</td>
<td align="left" nowrap valign="top" width="1%">&#160;</td>
<td align="left" nowrap valign="top" width="1%">&#160;</td>
<td align="left" colspan="2" valign="top" width="91%"><font size="2" style="FONT-FAMILY: times new roman">Consent of Independent Registered Public Accounting Firm.</font></td>
</tr><tr valign="bottom">
<td align="right" nowrap valign="top" width="5%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">&#160;&#160;&#160;&#160; 24.1</font></td>
<td align="right" nowrap valign="top" width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="left" nowrap valign="top" width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="left" nowrap valign="top" width="1%" bgcolor="#c0c0c0">&#160;</td>
<td align="left" colspan="2" valign="top" width="91%" bgcolor="#c0c0c0"><font size="2" style="FONT-FAMILY: times new roman">Power of Attorney (included on the signature page to this Registration Statement).</font></td>
</tr></table>
</div>

____________________<br>
&#160;<br>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="">
<tr>
<td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(1)</font></td>
<td nowrap valign="top">&#160;&#160;&#160;&#160;&#160;</td>
<td valign="top" width="100%"><font size="2" style="FONT-FAMILY: times new roman">Incorporated herein by reference from Exhibit 3.1 to the Registrant&#8217;s Registration Statement on Form S-1 (No. 333-05853) filed with the Securities and Exchange Commission on June 12, 1996.</font></td>
</tr><tr>
<td colspan="3" valign="top" width="100%">&#160;</td>
</tr><tr>
<td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(2)</font></td>
<td nowrap valign="top">&#160;</td>
<td valign="top" width="100%"><font size="2" style="FONT-FAMILY: times new roman">Incorporated herein by reference from Exhibit 3.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on July 31, 2006.</font></td>
</tr><tr>
<td colspan="3" valign="top" width="100%">&#160;</td>
</tr><tr>
<td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(3)</font></td>
<td nowrap valign="top">&#160;</td>
<td valign="top" width="100%"><font size="2" style="FONT-FAMILY: times new roman">Incorporated herein by reference from Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 19, 2010.</font></td>
</tr><tr>
<td colspan="3" valign="top" width="100%">&#160;</td>
</tr><tr>
<td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(4)</font></td>
<td nowrap valign="top">&#160;</td>
<td valign="top" width="100%"><font size="2" style="FONT-FAMILY: times new roman">Incorporated herein by reference from Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-1 (No. 333-05853) filed with the Securities and Exchange Commission on June 12, 1996.</font></td>
</tr><tr>
<td colspan="3" valign="top" width="100%">&#160;</td>
</tr><tr>
<td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(5)</font></td>
<td nowrap valign="top">&#160;</td>
<td valign="top" width="100%"><font size="2" style="FONT-FAMILY: times new roman">Incorporated herein by reference from Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 23, 2001.</font></td>
</tr><tr>
<td colspan="3" valign="top" width="100%">&#160;</td>
</tr><tr>
<td nowrap valign="top"><font size="2" style="FONT-FAMILY: times new roman">(6)</font></td>
<td nowrap valign="top">&#160;</td>
<td valign="top" width="100%"><font size="2" style="FONT-FAMILY: times new roman">Incorporated herein by reference from Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 7, 2011.</font></td>
</tr><tr>
<td colspan="3" valign="top" width="100%">&#160; </td>
</tr></table>
</div>

<hr align="center" noshade size="2" width="100%">
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>exhibit5-1.htm
<DESCRIPTION>OPINION OF LATHAM & WATKINS LLP.
<TEXT>
<html>
<head>
    <title>geron_s33.htm</title>
    <!-- Licensed to: DG3 I Docs, Inc. -->
    <!-- Document Created using EDGARizerAgent 5.3.0.0 -->
    <!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>


<body bgcolor="#ffffff">

<br>
<div style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">EXHIBIT 5.1 </font></font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">OPINION OF LATHAM &amp; WATKINS LLP</font></font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-FAMILY: Times New Roman"> </font></font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font size="2" style="FONT-FAMILY: Times New Roman">[Latham &amp; Watkins Letterhead] </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">January 7, 2011 </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">Geron Corporation </font></div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">230 Constitution Drive </font></div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">Menlo Park, CA 94025 </font></div>

<div>&#160;</div>

<div align="left">
<div>&#160;</div>

<div align="left">
<table bgcolor="white" cellpadding="0" cellspacing="0" width="100%" style="">
<tr>
<td valign="top" width="1%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Re:&#160; </font></td>
<td valign="top" width="99%"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Registration of 5,261,144 shares of common stock, $0.001 par value per share, of Geron Corporation, pursuant to a Registration Statement on Form S-3</font></td>
</tr></table>
</div>

<div>&#160;</div>
</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">Ladies and Gentlemen: </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;We have acted as special counsel to Geron Corporation, a Delaware corporation (the &#8220;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Company</font></font></font><font size="2" style="FONT-FAMILY: Times New Roman">&#8221;), in connection with the registration for resale of an aggregate of 5,261,144 shares of common stock, $0.001 par value per share (the &#8220;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Shares</font></font></font><font size="2" style="FONT-FAMILY: Times New Roman">&#8221;), issued to Angiochem, Inc., a corporation organized and existing under the laws of Canada (&#8220;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><
font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Angiochem</font></font></font><font size="2" style="FONT-FAMILY: Times New Roman">&#8221;), pursuant to the Common Stock Purchase Agreement dated as of January 5, 2011, by and between the Company and Angiochem. The Shares are included in a registration statement on Form S&#8211;3 under the Securities Act of 1933, as amended (the &#8220;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Act</font></font></font><font size="2" style="FONT-FAMILY: Times New Roman">&#8221;), filed with the Securities and Exchange Commission (the &#8220;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Commission</font></font></font><font size="2" style="FONT-FAMILY: Times New Roman">&#8221;) on January 7, 2011 (the &#82
20;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Registration Statement</font></font></font><font size="2" style="FONT-FAMILY: Times New Roman">&#8221;). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the related prospectus forming a part thereof (the &#8220;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font size="2" style="FONT-FAMILY: Times New Roman">Prospectus</font></font></font><font size="2" style="FONT-FAMILY: Times New Roman">&#8221;), other than as expressly stated herein with respect to the issue of the Shares. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware, and we express no opinion with respect to any other laws. </font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, the issue and sale of the Shares have been duly authorized by all necessary corporate action of the Company, and the Shares are validly issued, fully paid and nonassessable.</font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement and to the reference to our firm in the Prospectus under the heading &#8220;Validity of the Securities.&#8221; In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder. </font></div>

<div>&#160;</div>

<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse; ">
<tr valign="bottom">
<td align="left" nowrap width="50%">&#160;</td>
<td align="left" nowrap width="50%"><font size="2" style="FONT-FAMILY: times new roman">Very truly yours,</font></td>
</tr><tr>
<td align="left" nowrap width="50%">&#160;</td>
<td align="left" nowrap width="50%">&#160;</td>
</tr><tr valign="bottom">
<td align="left" nowrap width="50%">&#160;</td>
<td align="left" nowrap width="50%"><font size="2" style="FONT-FAMILY: times new roman">/s/ Latham &amp; Watkins LLP</font></td>
</tr></table>
</div>

<br>
<hr align="center" noshade size="2" width="100%">

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>exhibit23-2.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.
<TEXT>
<html>
<head>
    <title>geron_s33.htm</title>
    <!-- Licensed to: DG3 I Docs, Inc. -->
    <!-- Document Created using EDGARizerAgent 5.3.0.0 -->
    <!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>


<body bgcolor="#ffffff">

<br>
<div style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">EXHIBIT 23.2 </font></font></div>

<div>&#160;</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font size="2" style="FONT-FAMILY: Times New Roman">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></font><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="FONT-FAMILY: Times New Roman"> </font></font></div>

<div>&#160;</div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman"><font id="TAB2" style="LETTER-SPACING: 3pt">&#160;&#160;&#160;</font>&#160;We consent to the reference to our firm under the caption &#8220;Experts&#8221; in the Registration Statement (Form S-3) and related Prospectus of Geron Corporation for the registration of 5,261,144 shares of its common stock and to the incorporation by reference therein of our reports dated February 26, 2010, with respect to the consolidated financial statements of Geron Corporation and the effectiveness of internal control over financial reporting of Geron Corporation, included in its Annual Report (Form 10-K) for the year ended December 31, 2009, filed with the Securities and Exchange Commission. </font></div>

<div>&#160;</div>

<div>
<table border="0" cellpadding="0" cellspacing="0" width="100%" style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse; ">
<tr valign="bottom">
<td align="left" nowrap width="50%">&#160;</td>
<td align="left" nowrap width="50%"><font size="2" style="FONT-FAMILY: times new roman">/s/ Ernst &amp; Young LLP</font></td>
</tr><tr>
<td align="left" nowrap width="50%">&#160;</td>
<td align="left" nowrap width="50%">&#160; </td>
</tr></table>
</div>

<br>
<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">Palo Alto, California </font></div>

<div align="left"><font size="2" style="FONT-FAMILY: Times New Roman">January 6, 2011 </font></div>

<div>&#160;</div>

<hr align="center" noshade size="2" width="100%">
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
